US.LLY · Lilly (Eli)

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.5,
      "details": {
        "atrPct": 3.209475709339455,
        "turnoverUsdM": 3582.5323407312603,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.LLY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 1156.2501,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.5,
      "stop_loss_percent": 6.4,
      "take_profit_price": 1351.8814,
      "target_multiplier": 2.2,
      "technical_strength": 2,
      "take_profit_percent": 9.4
    },
    "positionPoints": 1.5,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.4644136381288617,
    "stopLossPercent": 6.41895141867891,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 68.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 60.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 1155.9715,
    "ma50": 1066.8518,
    "close": 1235.56,
    "prevClose": 1200.06,
    "avgVolume20": 3345381,
    "volumeRatio": 0.87,
    "changePercent": 2.96
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": 0.004577504224732243,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 0.8511193334341147,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.655551566804399,
      "volat_points": 0,
      "day_range_pct": 0.021407255589016,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 68.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 14,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 70,
        "contribution": 14
      },
      {
        "raw": 7.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 50.67,
        "contribution": 7.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.9,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 69,
        "contribution": 6.9
      },
      {
        "raw": 21,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 70,
        "contribution": 21
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 60.5,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 14/20分",
      "市場環境分析總分: 7.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.9/10分",
      "技術信號分析總分: 21/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 14,
      "市場環境": 7.6,
      "情緒分析": 4,
      "技術信號": 21,
      "風險管理": 6.9
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 3582.5323407312603,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.LLY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.57
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 720.4330052000001,
                "ma50": 711.66400144,
                "name": "QQQ",
                "close": 709.42999,
                "points": 0.4
              },
              "spy": {
                "ma20": 741.2935059,
                "ma50": 739.0122021000002,
                "name": "SPY",
                "close": 747.71002,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.209475709339455,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140835348,
                "url": "https://finnhub.io/api/news?id=a68c3d66200725b6473b4584c3bc6f68298be95f9834ad53e0ac6f61645c3d46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating.",
                "category": "company",
                "datetime": 1783459792,
                "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today"
              },
              {
                "id": 140835349,
                "url": "https://finnhub.io/api/news?id=932035aea36b61000d4c1bf7e2ad6926ed1243d7766729c37fe7af450e5e291d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) is back in focus after handing Chinese partner Innovent Biologics full commercial control of breast cancer drug Verzenios, a shift that raises fresh questions about how the stock’s premium valuation stacks up. See our latest analysis for Eli Lilly. Verzenios is only one piece of a much bigger story for Eli Lilly. The stock gave back some ground in the latest session as the share price fell 1.14% to US$1,200.06, yet it is still showing firm momentum with a 30 day share price...",
                "category": "company",
                "datetime": 1783459022,
                "headline": "Eli Lilly (LLY) After The China Verzenios Shift And The Valuation Debate"
              },
              {
                "id": 140826482,
                "url": "https://finnhub.io/api/news?id=3a590d94bb8a5e39c7a7de303c8b10521892143450164c440da563676b4aabbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has entered a new research collaboration with Abbisko Cayman Limited, focused on expanding its pipeline through external R&D partnerships. The company has transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics, adjusting its approach in that market. Eli Lilly has become closely associated with obesity and diabetes treatments, but this latest update shows the company putting more emphasis on partnerships and regional focus. The Abbisko...",
                "category": "company",
                "datetime": 1783394364,
                "headline": "Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover"
              },
              {
                "id": 140825341,
                "url": "https://finnhub.io/api/news?id=143fd72effdf00e1ce394af1b2aa7526b7dfbe381380230cd89797d71a5c1cf6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783374306,
                "headline": "Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade"
              },
              {
                "id": 140821035,
                "url": "https://finnhub.io/api/news?id=7fa95457115790ffbd3d459fee8f39e9e781a7aaa3f4b07c34fb7ce24ca002a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q1 2026 investor letter. A copy of the letter can be downloaded here. The US stock market declined in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth index (“RLG”) […]",
                "category": "company",
                "datetime": 1783348747,
                "headline": "Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges"
              },
              {
                "id": 140821036,
                "url": "https://finnhub.io/api/news?id=091fa09d558dc0bb8e7d188c4ea5116dfe45df7bf62cba0bf3ee94576ee056cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783342805,
                "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know"
              },
              {
                "id": 140810623,
                "url": "https://finnhub.io/api/news?id=5b3563dee0c2e0067d9c7222e8655c15df08ec6d9e58e13dbbecdf6e9c5fdf12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside. A roughly 441.5% return over five years puts Eli Lilly among the stronger long term performers, which raises the bar for what counts as an attractive entry point. Expectations around the GLP-1 obesity and diabetes franchise can...",
                "category": "company",
                "datetime": 1783221407,
                "headline": "Eli Lilly (LLY) Stock May Trade At A Cash Flow Discount But An Earnings Premium"
              },
              {
                "id": 140784654,
                "url": "https://finnhub.io/api/news?id=c32b8d8067a978de3e864c5eed8c51b9f7ac2a4641abd9e48c8b80e4a40fbd6c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Eli Lilly and Company (NYSE:LLY) released additional details about the Medicare GLP-1 Bridge program, where it explained how eligible Medicare Part D patients can access its two weight management drugs for a flat $50 per month […]",
                "category": "company",
                "datetime": 1782941602,
                "headline": "Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?"
              }
            ],
            "raw_source": [
              {
                "id": 140835334,
                "url": "https://finnhub.io/api/news?id=bd1040ad78b4ba83c41404d543c505aa24d8b557ebf9f66fdf37f149c144460e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Nasdaq led the stock market lower Tuesday, as Samsung earnings slammed AI names. Oil prices jumped on U.S.-Iran news.",
                "category": "company",
                "datetime": 1783461141,
                "headline": "Dow Jones Futures: Nasdaq Slumps As Samsung Fans AI Fears, Oil Prices Jump On Iran News"
              },
              {
                "id": 140835347,
                "url": "https://finnhub.io/api/news?id=7c2ba7baa099679035fad5170d750e7121c1446d52ed53d54af19195f6b4a2f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Don't sleep on these medical device leaders.",
                "category": "company",
                "datetime": 1783461000,
                "headline": "Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom"
              },
              {
                "id": 140835348,
                "url": "https://finnhub.io/api/news?id=a68c3d66200725b6473b4584c3bc6f68298be95f9834ad53e0ac6f61645c3d46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating.",
                "category": "company",
                "datetime": 1783459792,
                "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today"
              },
              {
                "id": 140835349,
                "url": "https://finnhub.io/api/news?id=932035aea36b61000d4c1bf7e2ad6926ed1243d7766729c37fe7af450e5e291d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) is back in focus after handing Chinese partner Innovent Biologics full commercial control of breast cancer drug Verzenios, a shift that raises fresh questions about how the stock’s premium valuation stacks up. See our latest analysis for Eli Lilly. Verzenios is only one piece of a much bigger story for Eli Lilly. The stock gave back some ground in the latest session as the share price fell 1.14% to US$1,200.06, yet it is still showing firm momentum with a 30 day share price...",
                "category": "company",
                "datetime": 1783459022,
                "headline": "Eli Lilly (LLY) After The China Verzenios Shift And The Valuation Debate"
              },
              {
                "id": 140835338,
                "url": "https://finnhub.io/api/news?id=94b905cd04ca6b79a67ba855f8e46511577233b1c5fbd2891b5cc25d77cf31df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Stock Market Today: The Nasdaq falls. IBM stock is a big Dow Jones index winner. Micron and Lam Research sell-off.",
                "category": "company",
                "datetime": 1783456555,
                "headline": "Stock Market Today: Nasdaq Is Day's Biggest Loser; Sandisk, Micron Tumble, Eli Lilly Shines"
              },
              {
                "id": 140835351,
                "url": "https://finnhub.io/api/news?id=260d72247d9f70efd510e08c54abe96362e0ed8be882639886d666c621748268",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock is down, but it isn't out yet.",
                "category": "company",
                "datetime": 1783455600,
                "headline": "3 Reasons to Buy Novo Nordisk Stock"
              },
              {
                "id": 140835352,
                "url": "https://finnhub.io/api/news?id=cde7c44a0e7ab15b40a678d6dc96c3f9be5c0f283a2690eb28957cfa2f295b37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S",
                "category": "company",
                "datetime": 1783453906,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 140835353,
                "url": "https://finnhub.io/api/news?id=c4f382b5352bbe5ca224d50764aeb31d6d4bba886603869762d997d1bc75054d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Construction at  Pfizer’s  former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues.  The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the  index, at more than 7%.  Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.",
                "category": "company",
                "datetime": 1783452120,
                "headline": "Former Pfizer Building Is Crumbling—Just as the Stock Has"
              },
              {
                "id": 140834188,
                "url": "https://finnhub.io/api/news?id=348634c830c438627985655c14385ec6bba641b5b23f9982edb7893e2b40441c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drug stocks got hit hard on Monday in what Jim Cramer called a “vicious rotation,” and the selloff looked like the usual crowded-trade unwind. Investors decided the Mounjaro story was played out. On Tuesday morning’s Mad Dash, Cramer walked through why he thinks that reading is wrong, and he had a fresh JPMorgan note flagging ... Everyone Thinks the Eli Lilly Story Is Played Out. Cramer Thinks They’re Dead Wrong",
                "category": "company",
                "datetime": 1783450513,
                "headline": "Everyone Thinks the Eli Lilly Story Is Played Out. Cramer Thinks They’re Dead Wrong"
              },
              {
                "id": 140834189,
                "url": "https://finnhub.io/api/news?id=720d1fcb511546fccf6918a9df0be6c8000abd30049807e1f14940c8e6c06704",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.",
                "category": "company",
                "datetime": 1783449300,
                "headline": "U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend"
              },
              {
                "id": 140832950,
                "url": "https://finnhub.io/api/news?id=ac61b8fece0a82acca5929c41d3524911484cfd075f8c84f5e2c80822f18058d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.",
                "category": "company",
                "datetime": 1783444509,
                "headline": "Eli Lilly's Market Cap Balloons Again On This IPO's Setback"
              },
              {
                "id": 140829898,
                "url": "https://finnhub.io/api/news?id=0add1b096141ec74b3d6cd8f42c09bb8ff6335d4e57ffb6497dbd39245915f1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Stock Market Today: The Dow Jones index rose, while the Nasdaq dropped amid Samsung earnings. Micron and Sandisk plunged.",
                "category": "company",
                "datetime": 1783444206,
                "headline": "Stock Market Today: Nasdaq Slides As Samsung Tumbles On Earnings; Micron, Sandisk Lose Big (Live Coverage)"
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140831226,
                "url": "https://finnhub.io/api/news?id=94f144166168679378f28a9665f1a5495f8b74e073cab0d967c8a5aa5245a37e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of Eli Lilly have risen by over 40% since the company last reported earnings.",
                "category": "company",
                "datetime": 1783437600,
                "headline": "Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?"
              },
              {
                "id": 140833518,
                "url": "https://finnhub.io/api/news?id=22ce4f0fa67e4136661f31216b954cf91434f87aec814df743617df48808aaad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk A/S is downgraded to Hold as competitive and margin pressures mount and growth slows. Learn more about NVO stock here.",
                "category": "company",
                "datetime": 1783434261,
                "headline": "Novo Nordisk Loses Its Edge, And I'm Downgrading"
              },
              {
                "id": 140831295,
                "url": "https://finnhub.io/api/news?id=3f5c10eed8e8606ed043e3df2f6b863e7bcce6f39900fce931d599a7f1c0dcb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.",
                "category": "company",
                "datetime": 1783429260,
                "headline": "Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?"
              },
              {
                "id": 140830043,
                "url": "https://finnhub.io/api/news?id=8357ba81dbd79358869a1770871886a7b1d9d6810dbf75dc63f20d672ac87ab3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.",
                "category": "company",
                "datetime": 1783427400,
                "headline": "Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years."
              },
              {
                "id": 140832953,
                "url": "https://finnhub.io/api/news?id=0b0e3f54345030becaf6700bd9e31df194ccd771d9fd5ec5d58b3aaac62348f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.",
                "category": "company",
                "datetime": 1783426620,
                "headline": "Oberland pours up to $400M into MeiraGTx eye gene therapies"
              },
              {
                "id": 140832954,
                "url": "https://finnhub.io/api/news?id=a263dce72b44aac5f3ccd27014b3814ee84a251c4e6383adc83c7b4c8bb5e79d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.",
                "category": "company",
                "datetime": 1783425592,
                "headline": "Kailera says obesity pill succeeds in late-stage trial in China"
              },
              {
                "id": 140833610,
                "url": "https://finnhub.io/api/news?id=0bdbb88c83cae49361eab3458ab8eaf17cf801bfae72dff0a015223b2b494a87",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly Canada announced today that Mounjaro® (tirzepatide), the first and only Health Canada-authorized once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor",
                "category": "company",
                "datetime": 1783423485,
                "headline": "Reported Earlier: Eli Lilly's Mounjaro Receives Health Canada Approval To Treat Children 10 Years, Older With Type 2 Diabetes"
              },
              {
                "id": 140829123,
                "url": "https://finnhub.io/api/news?id=37a2108fec9094606f3ebe5d5ff4e2b0ae74d3503d5a4911ba6c5ed9c686f3f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY, HSBC and PLTR headline new research as growth drivers, strategic initiatives and key risks shape the latest outlooks for these companies.",
                "category": "company",
                "datetime": 1783419780,
                "headline": "The Zacks Analyst Blog Highlights Eli Lilly, HSBC, Palantir and CBL & Associates"
              },
              {
                "id": 140830464,
                "url": "https://finnhub.io/api/news?id=52f5b12a0e9e9f0e61b5c3a6ed63d8c338dd909d7f128d2ca79318d7e9b6fc10",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222724/image_2194222724.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Altimmune, Inc. upgraded to Buy after $535m raise funds Phase 3 MASH trials; pemvidutide data and catalysts vs GLP-1 rivals. Click for this ALT stock update.",
                "category": "company",
                "datetime": 1783419366,
                "headline": "Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade"
              },
              {
                "id": 140830465,
                "url": "https://finnhub.io/api/news?id=e0b7e923d5f8e72f7db716b335ec70d8a45cdc7266f8d8f0ebc5eb2bc6f6bc3f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/464406694/image_464406694.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Q2 of 2026 started with a white-hot rally in the stock market, recovering its losses from the first quarter and setting several record highs throughout April (+10.4%) and May (+5.15).",
                "category": "company",
                "datetime": 1783419120,
                "headline": "Andrew Hill Investment Advisors' Q2 2026 Significant Positions"
              },
              {
                "id": 140832353,
                "url": "https://finnhub.io/api/news?id=a10ad746a2ffa6e59e3235174c29cf20b0bffae400b96c51c0bcba58bdbbd74e",
                "image": "https://image.cnbcfm.com/api/v1/image/108331424-17834307751783430773-47014189223-1080pnbcnews.jpg?v=1783430774&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1783416531,
                "headline": "Cramer’s Mad Dash: Eli Lilly"
              },
              {
                "id": 140830044,
                "url": "https://finnhub.io/api/news?id=a525b2f107ac14ff07317a5d0fd2a984f07cf0426b0135b325b8d65da9b43696",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.",
                "category": "company",
                "datetime": 1783413771,
                "headline": "Can anyone catch up to Eli Lilly?"
              },
              {
                "id": 140829567,
                "url": "https://finnhub.io/api/news?id=736265c3bcf026a1c9eaf58c5f2d746749e1e592e9b0699d74bef818c0ec74df",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183695394/image_2183695394.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novartis bolsters its ADC pipeline via Myricx Bio deal, while Avidity del-brax and Ionis pelacarsen near pivotal readouts—see what to watch now.",
                "category": "company",
                "datetime": 1783413652,
                "headline": "Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon"
              },
              {
                "id": 140833611,
                "url": "https://finnhub.io/api/news?id=ab7a1216a78dc201bce1f5d58771f4b687a3ba25225dc733fb08a9eb9a3cfeff",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "JP Morgan  analyst Chris Schott   maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1300 to $1400.",
                "category": "company",
                "datetime": 1783412892,
                "headline": "JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1400"
              },
              {
                "id": 140826482,
                "url": "https://finnhub.io/api/news?id=3a590d94bb8a5e39c7a7de303c8b10521892143450164c440da563676b4aabbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has entered a new research collaboration with Abbisko Cayman Limited, focused on expanding its pipeline through external R&D partnerships. The company has transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics, adjusting its approach in that market. Eli Lilly has become closely associated with obesity and diabetes treatments, but this latest update shows the company putting more emphasis on partnerships and regional focus. The Abbisko...",
                "category": "company",
                "datetime": 1783394364,
                "headline": "Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover"
              },
              {
                "id": 140825341,
                "url": "https://finnhub.io/api/news?id=143fd72effdf00e1ce394af1b2aa7526b7dfbe381380230cd89797d71a5c1cf6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783374306,
                "headline": "Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade"
              },
              {
                "id": 140824416,
                "url": "https://finnhub.io/api/news?id=58ac94e21051c144761f39b4ccf2c7a30a2aabc76ed7c222a0a92310c75b10a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly, HSBC and Palantir headline Zacks' latest top stock reports, highlighting growth drivers, opportunities and key risks shaping each outlook.",
                "category": "company",
                "datetime": 1783369560,
                "headline": "Top Stock Reports for Eli Lilly, HSBC & Palantir"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140834190,
                "url": "https://finnhub.io/api/news?id=f3324565e3587a0bf54bca6c0aef4947e4d169260b8a95c59daa073ebddf4393",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.",
                "category": "company",
                "datetime": 1783362000,
                "headline": "As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner"
              },
              {
                "id": 140823559,
                "url": "https://finnhub.io/api/news?id=5a144f07bedba347af467925be73da106be1e89722253a4d07e63d464f1aecad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.",
                "category": "company",
                "datetime": 1783361040,
                "headline": "3 Healthcare ETFs to Own in a Choppy Stock Market"
              },
              {
                "id": 140832183,
                "url": "https://finnhub.io/api/news?id=1f8724f063d5dc11fab072e2e81fa24b43a1162feb8cfbde707331beeceeef3e",
                "image": "https://image.cnbcfm.com/api/v1/image/108327424-1782483651570-gettyimages-2283426563-mms23629_eqrvbr4g.jpeg?v=1782483791&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The Dow Jones Industrial Average hit a fresh all-time intraday high on Tuesday.",
                "category": "company",
                "datetime": 1783360907,
                "headline": "Dow turns red as chip stocks tumble, oil prices gain: Live updates"
              },
              {
                "id": 140822441,
                "url": "https://finnhub.io/api/news?id=a8a1b28066f6e208b8e9c7195cc557e003be78ce757401f35ac4df52844cd88e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.",
                "category": "company",
                "datetime": 1783358941,
                "headline": "Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140821313,
                "url": "https://finnhub.io/api/news?id=9fe92ea43d36be6f3f609d8d2a019dbf34037595ad1f25b61db9491fca7f39ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As the Nasdaq shakes off a recent spat of volatility, Eli Lilly, Affirm. Twilio and BillionToOne come into focus.",
                "category": "company",
                "datetime": 1783353447,
                "headline": "Lilly, This IPO Leader Among Stocks To Watch In A Mischievous Market"
              },
              {
                "id": 140821033,
                "url": "https://finnhub.io/api/news?id=4c61cc364714533bd4f04c0f59c93534543bbcf3cc26ac7b0713b270e8efaada",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.",
                "category": "company",
                "datetime": 1783352496,
                "headline": "Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into Earnings"
              },
              {
                "id": 140821034,
                "url": "https://finnhub.io/api/news?id=65c5fe79f348769158d94604c63c830cdd5ebdaaaf0ad0c38b1a70992d53e932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over",
                "category": "company",
                "datetime": 1783350767,
                "headline": "Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says"
              },
              {
                "id": 140822443,
                "url": "https://finnhub.io/api/news?id=e98b4572e6d9ffe70502143f9879e30e50ff8303c76022fdc0e9700f2d9eb925",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.",
                "category": "company",
                "datetime": 1783349400,
                "headline": "Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?"
              },
              {
                "id": 140821035,
                "url": "https://finnhub.io/api/news?id=7fa95457115790ffbd3d459fee8f39e9e781a7aaa3f4b07c34fb7ce24ca002a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q1 2026 investor letter. A copy of the letter can be downloaded here. The US stock market declined in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth index (“RLG”) […]",
                "category": "company",
                "datetime": 1783348747,
                "headline": "Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges"
              },
              {
                "id": 140824618,
                "url": "https://finnhub.io/api/news?id=1cd268edbc835f22e1ed85b0dc0df50fb53a9d0098a14558c26e1aa4b1f18494",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783344935,
                "headline": "8 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140821036,
                "url": "https://finnhub.io/api/news?id=091fa09d558dc0bb8e7d188c4ea5116dfe45df7bf62cba0bf3ee94576ee056cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783342805,
                "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know"
              },
              {
                "id": 140819146,
                "url": "https://finnhub.io/api/news?id=f25edd9ab45af7d58bc394a2e0c53e3cba34b2b823f1ac2f00fe4ae0eee37a7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.",
                "category": "company",
                "datetime": 1783337700,
                "headline": "Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?"
              },
              {
                "id": 140819912,
                "url": "https://finnhub.io/api/news?id=b5d2bd20e0a76d685d7676d5181354c92bbb779edc1b0cc1076343be0a7f6da6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/628093148/image_628093148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they lag AI names. Click for the picks.",
                "category": "company",
                "datetime": 1783331728,
                "headline": "My Top 5 Pharma Stocks Wall Street Ignores"
              },
              {
                "id": 140821903,
                "url": "https://finnhub.io/api/news?id=50d9afed06e6b3f532ca2d55665edd1038daea96dd4f3c25a97bc0e80ba7cea9",
                "image": "https://image.cnbcfm.com/api/v1/image/108330802-17833443451783344342-46993064617-1080pnbcnews.jpg?v=1783344344&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1783330243,
                "headline": "Cramer’s Mad Dash: iShares Biotechnology ETF"
              },
              {
                "id": 140818369,
                "url": "https://finnhub.io/api/news?id=4c32b27394b38ba6381a237313ff0ef121847a538c2610757affbb35dc453f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly offers investors safety and growth.",
                "category": "company",
                "datetime": 1783330200,
                "headline": "Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.)"
              },
              {
                "id": 140820663,
                "url": "https://finnhub.io/api/news?id=963431739cd80c6cb509031afa2f886fe8e816f995942ef106f95370de162f9c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1230 to $1350.",
                "category": "company",
                "datetime": 1783327829,
                "headline": "Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1350"
              },
              {
                "id": 140816324,
                "url": "https://finnhub.io/api/news?id=394e6d817f0f1e1d3946ce3afe40d22f68f5826a5a03b1edfbb7d09670ef8155",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its weight-loss drugs. Away from that spotlight, the drugmaker made changes to a smaller corner of its business in its second-largest market. On June 30, Lilly agreed to hand a Chinese partner full ...",
                "category": "company",
                "datetime": 1783298220,
                "headline": "Lilly quietly hands Chinese partner its cancer drug"
              },
              {
                "id": 140820581,
                "url": "https://finnhub.io/api/news?id=d78c036b50e519b565344311a0d3db62f47be1f8e694fcce308d14cfbc7f99d2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/05/Elizabeth-Warren.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while also challenging TrumpRx's impact on drug costs.",
                "category": "company",
                "datetime": 1783260507,
                "headline": "Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States"
              },
              {
                "id": 140811025,
                "url": "https://finnhub.io/api/news?id=f1e9d64db37cc17e48b64ec74cb4e47eb945bd402723d911b0c3f5a4316d123c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This biotech might have a bright future, but it'll need to survive against the incumbents to do so.",
                "category": "company",
                "datetime": 1783229100,
                "headline": "How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?"
              },
              {
                "id": 140810623,
                "url": "https://finnhub.io/api/news?id=5b3563dee0c2e0067d9c7222e8655c15df08ec6d9e58e13dbbecdf6e9c5fdf12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside. A roughly 441.5% return over five years puts Eli Lilly among the stronger long term performers, which raises the bar for what counts as an attractive entry point. Expectations around the GLP-1 obesity and diabetes franchise can...",
                "category": "company",
                "datetime": 1783221407,
                "headline": "Eli Lilly (LLY) Stock May Trade At A Cash Flow Discount But An Earnings Premium"
              },
              {
                "id": 140808870,
                "url": "https://finnhub.io/api/news?id=4cfa6cb316fb31dbcc6c60b49db48b80587d0e854ad955c1e9f9c51cae161447",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now. GLP-1 Fireworks ... Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly",
                "category": "company",
                "datetime": 1783188027,
                "headline": "Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly"
              },
              {
                "id": 140805979,
                "url": "https://finnhub.io/api/news?id=151119961c9183fc98dfd478858adc35b96c4b85974f02c4c5820e14a9cf0302",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock is known to soar on good news.",
                "category": "company",
                "datetime": 1783157400,
                "headline": "Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying"
              },
              {
                "id": 140805197,
                "url": "https://finnhub.io/api/news?id=7ebab30bd35d0b44b0b78d9854944513fc2c795ba351b018ff1fa20b3e0e26ae",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214049905/image_2214049905.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Explore the 4-Factor dividend growth strategy vs SCHD: returns, recent momentum shifts, and a new ROC/PEG variant test.",
                "category": "company",
                "datetime": 1783134898,
                "headline": "SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For July 2026"
              },
              {
                "id": 140804159,
                "url": "https://finnhub.io/api/news?id=eb0bdae932b392a1a0224645bd5ef4d6b9bab66a17109585e57c61183ab4775b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.",
                "category": "company",
                "datetime": 1783128900,
                "headline": "Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?"
              },
              {
                "id": 140799479,
                "url": "https://finnhub.io/api/news?id=570bbb3b7612cc003af58247147d83f6864848d84ec833834a2195433c105740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.",
                "category": "company",
                "datetime": 1783086339,
                "headline": "Here's Why Viking Therapeutics Stock Surged Higher in June"
              },
              {
                "id": 140802433,
                "url": "https://finnhub.io/api/news?id=62723bd3c7a9defce0d3ae2513b6b9539026160175ddd370ab9c4da81406ba8d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783085724,
                "headline": "8 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 140800008,
                "url": "https://finnhub.io/api/news?id=700a5668d8a7f5f25768a0ea6ab4bddf4389c2f5ed87cbb96053d72b31d8335b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.",
                "category": "company",
                "datetime": 1783084320,
                "headline": "Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?"
              },
              {
                "id": 140800334,
                "url": "https://finnhub.io/api/news?id=775d6dab566b5db31d75eeaf69c62d346930e076c98148765df6a63feec194c7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2262213088/image_2262213088.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Hims & Hers' stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Click to learn more.",
                "category": "company",
                "datetime": 1783078165,
                "headline": "HIMS Breakout Signals Structural Business Transformation"
              },
              {
                "id": 140798353,
                "url": "https://finnhub.io/api/news?id=af3ce6803222543543796d3613fb7b8ebe9f7614e6f6a9734ddef35d29886348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Antidiabetic Drugs Market size & share revenue was valued at approximately USD 103.21 Billion in 2025 and is expected to reach USD 115.02 Billion in 2026 and is expected to reach around USD 309.84 Billion by 2035, at a CAGR of 11.62% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Eli Lilly and Company,",
                "category": "company",
                "datetime": 1783067400,
                "headline": "[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140800592,
                "url": "https://finnhub.io/api/news?id=69906ae48e307e5378519c5fff630ed122b3c26f7a4c9b4e01447169d34e83d9",
                "image": "https://image.cnbcfm.com/api/v1/image/108330387-17830466841783046680-46921287425-1080pnbcnews.jpg?v=1783046683&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own pipeline and become a top global player in AI drug discovery. He breaks down the deal's structure, roughly sixty million upfront with the remaining six hundred million tied to milestones and royalties, and points to Insilico's thirty one developmental candidates as proof its platform delivers real drugs, not just software.",
                "category": "company",
                "datetime": 1783033106,
                "headline": "Takeda deal lets us scale our capabilities: Insilico Medicine CEO"
              },
              {
                "id": 140792959,
                "url": "https://finnhub.io/api/news?id=ee6da6462659dfa08361afe62be1aecd7ac76b797f01f38b6a14f5d8d0d35fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.",
                "category": "company",
                "datetime": 1783013373,
                "headline": "JNJ Stock Management Sees A Breakout, The Market Sees A Standoff"
              },
              {
                "id": 140792960,
                "url": "https://finnhub.io/api/news?id=39203cbd19d0e0964e04d51a7e2668f24e017056d2c729bece459fd043d79c36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks are attracting attention in a market broadening beyond AI-driven tech names, and now make up a big chunk of the IBD 50 list.",
                "category": "company",
                "datetime": 1783008478,
                "headline": "Healthcare Stocks Rise To The Heart Of IBD's Elite List Of Growth Names"
              },
              {
                "id": 140792961,
                "url": "https://finnhub.io/api/news?id=56ace9e8f9a3601c5c52f7e264cce2da28a30e17b535a2b0bb8be19b8729298e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...",
                "category": "company",
                "datetime": 1783008180,
                "headline": "House committee investigates Merck, AbbVie over China trials"
              },
              {
                "id": 140800595,
                "url": "https://finnhub.io/api/news?id=d496e3fa576899848e38d53aa49bd5f7bcaf860c9b143f35ea2324fecbf3ac1c",
                "image": "https://image.cnbcfm.com/api/v1/image/108330186-1783019122904-1783018967-46914473154-hd.jpg?v=1783019124&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Jeff Kilburg, founder and CEO of KKM Financial, joins \"Power Lunch\" to discuss the growing interest in healthcare stocks.",
                "category": "company",
                "datetime": 1783004742,
                "headline": "KKM's Jeff Kilburg explains the healthcare trade in the second half of 2026"
              },
              {
                "id": 140792240,
                "url": "https://finnhub.io/api/news?id=aa7ae8323898ac9799ace5b95b382097f18826aa19687048e1f685b485f1aacd",
                "image": "https://image.cnbcfm.com/api/v1/image/108330088-17830116761783011673-46912650250-1080pnbcnews.jpg?v=1783011675&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Brad Gerstner, Founder and CEO of Altimeter Capital, joins CNBC's \"Halftime Report” to talk about Trump Accounts launching on July 4th.",
                "category": "company",
                "datetime": 1782998357,
                "headline": "Altimeter's Brad Gerstner on Trump Accounts Launching on July 4th"
              },
              {
                "id": 140800263,
                "url": "https://finnhub.io/api/news?id=f114a66df55bc308a71df96eb51d64a46d1e4cd9f81215e4d1fd64468dcd44c7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/02/Doctor-Hand-Point-Patient-Lung-X-ray-Fil.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Abbisko and AstraZeneca will jointly develop a Phase 1/2 NSCLC therapy combining lumipodlin with Tagrisso after China's IND clearance.",
                "category": "company",
                "datetime": 1782997542,
                "headline": "Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance"
              },
              {
                "id": 140792339,
                "url": "https://finnhub.io/api/news?id=f9dcb503fefd60269c149e9f76bae28991b4905519c4b88be1bdf0e96cf47400",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/02/NYSE-and-Wall-St.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The Dow hit a record after a weak June jobs report eased Fed rate-hike fears, but a sharp semiconductor rout dragged the Nasdaq 100 lower Thursday.",
                "category": "company",
                "datetime": 1782996982,
                "headline": "Dow Jones Hits Record High as Chip Bloodbath Sinks Nasdaq 100: Stock Market Today"
              },
              {
                "id": 140791356,
                "url": "https://finnhub.io/api/news?id=10cc6cdf9451e8fd98ab98a531cb0ea5c72dfa0d3423e4b2e217404d101249f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.",
                "category": "company",
                "datetime": 1782996540,
                "headline": "Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 140790463,
                "url": "https://finnhub.io/api/news?id=10f0b33a809a877b563a9f52ce1db4964c98a359ae660cae66a446c49b226eb3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.",
                "category": "company",
                "datetime": 1782984578,
                "headline": "Can pharma sustain its $2T trajectory?"
              },
              {
                "id": 140784654,
                "url": "https://finnhub.io/api/news?id=c32b8d8067a978de3e864c5eed8c51b9f7ac2a4641abd9e48c8b80e4a40fbd6c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Eli Lilly and Company (NYSE:LLY) released additional details about the Medicare GLP-1 Bridge program, where it explained how eligible Medicare Part D patients can access its two weight management drugs for a flat $50 per month […]",
                "category": "company",
                "datetime": 1782941602,
                "headline": "Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?"
              },
              {
                "id": 140782442,
                "url": "https://finnhub.io/api/news?id=a82e2ba1fdf0d4389a81fed4330217d2025311cc1fbb1cd0153cbabe5ff6407a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43. We rate LLY a buy with a 90% confidence score. The GLP-1 franchise is compounding faster than the market appreciated last spring, and Foundayo just opened a scalable oral channel to more than ... Eli Lilly Price Prediction: The Case for Double-Digit Upside",
                "category": "company",
                "datetime": 1782926312,
                "headline": "Eli Lilly Price Prediction: The Case for Double-Digit Upside"
              },
              {
                "id": 140792241,
                "url": "https://finnhub.io/api/news?id=26c5b63d838ff9c886771807f4937f9c7d7bdc029a80e7025dd3cc90fb1fe283",
                "image": "https://image.cnbcfm.com/api/v1/image/108329591-17829377401782937737-46894974430-1080pnbcnews.jpg?v=1782937739&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s “Closing Bell Overtime” team discusses whether recent momentum can last in the healthcare trade and how investors can diversify with Ayako Yoshioka, senior investment strategist at Wealth Enhancement.",
                "category": "company",
                "datetime": 1782923971,
                "headline": "Healthcare trade offers demand characteristics not tied to AI: Wealth Enhancement's Yoshioka"
              },
              {
                "id": 140792242,
                "url": "https://finnhub.io/api/news?id=53facab81d989721b5c9369c777ca48725ba2e678cfaaa7c80f49f9fa21a6d57",
                "image": "https://image.cnbcfm.com/api/v1/image/108329580-17829362031782936201-46894576955-1080pnbcnews.jpg?v=1782936202&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Scott Wapner discusses why tech may be primed for a correction with Doug Clinton of Intelligent Alpha.",
                "category": "company",
                "datetime": 1782922254,
                "headline": "Wouldn't be surprised if Nasdaq saw 10% correction, says Intelligent Alpha's Clinton"
              },
              {
                "id": 140780516,
                "url": "https://finnhub.io/api/news?id=3a7b15204a13ad3450467bc3587747bf74035704bb1712cddf2598d1e26d9c36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "If you sort all the top politicians with a portfolio of above $1 million using their annual gains, who do you expect at the top? Likely Nancy Pelosi, but that’s not the case. A Republican Senator named Ashley Moody has gained 310% in the past year using her portfolio. Her portfolio and her (lack of) ... New Nancy Pelosi? Senator Ashley Moody Up 310% in One Year With These Stocks",
                "category": "company",
                "datetime": 1782921037,
                "headline": "New Nancy Pelosi? Senator Ashley Moody Up 310% in One Year With These Stocks"
              },
              {
                "id": 140792243,
                "url": "https://finnhub.io/api/news?id=45b5c64c99f92da25d0a81cfa20a1a98a379cf5285f0fdf76a67d103398bed57",
                "image": "https://image.cnbcfm.com/api/v1/image/103437310-GettyImages-181179427.jpg?v=1608663124&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Medicare has started covering obesity drugs for the first time – and companies like Walmart and CVS Health are playing an important role for patients. ",
                "category": "company",
                "datetime": 1782916901,
                "headline": "Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs "
              },
              {
                "id": 140783647,
                "url": "https://finnhub.io/api/news?id=5066bf226a6e9a856813ce0b0d0da329608b543b7c57933205ecd336be1f3901",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.",
                "category": "company",
                "datetime": 1782915791,
                "headline": "Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results"
              },
              {
                "id": 140779451,
                "url": "https://finnhub.io/api/news?id=523b2956383e6b450ea7788c809b0fecf4cdb1c62186fa4f1ed46aa648ec5426",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "U.S. lawmakers have opened a national security probe into Eli Lilly's (NYSE:LLY) clinical trial activities in China. The House Select Committee on China is seeking detailed information on trial oversight, data access, and ties to Chinese institutions. Lawmakers have set a July 17 deadline for Eli Lilly to respond with documents and explanations. Eli Lilly is a major global pharmaceutical company with a large portfolio across diabetes, obesity, oncology, immunology, and other therapeutic...",
                "category": "company",
                "datetime": 1782911873,
                "headline": "Eli Lilly (LLY) Faces China Trial Security Probe From U.S. Lawmakers"
              },
              {
                "id": 140791144,
                "url": "https://finnhub.io/api/news?id=296da59202b329e94eb30e441728d2248e767c13e8d3682da006e1acea6629a2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/01/Eli-Lilly-and-Co.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.",
                "category": "company",
                "datetime": 1782911358,
                "headline": "Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China"
              },
              {
                "id": 140779369,
                "url": "https://finnhub.io/api/news?id=3ce8901c46eab38f26e764781e12116d37a1a7295cb47bd7ff12f69157433a2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure",
                "category": "company",
                "datetime": 1782911072,
                "headline": "Cathie Wood's Biggest Portfolio Moves Reveal Where She's Betting Next"
              },
              {
                "id": 140780654,
                "url": "https://finnhub.io/api/news?id=1bd01f8e61ef51ebcb51cb5b0359bbb686d74196259eb0aebb6161b83b544b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.",
                "category": "company",
                "datetime": 1782911040,
                "headline": "Amgen or Biogen: Which Biotech Stock Appears Better Poised?"
              },
              {
                "id": 140779453,
                "url": "https://finnhub.io/api/news?id=1f0144a5843ade494aec0ed3fa018b39a33281af4aeca74010f3884599175c62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Altria stand out as defensive stock ideas as investors weigh a hawkish Fed, a pivotal jobs report and shifting market leadership.",
                "category": "company",
                "datetime": 1782909240,
                "headline": "Zacks Investment Ideas feature highlights: Eli Lilly and Altria"
              },
              {
                "id": 140779454,
                "url": "https://finnhub.io/api/news?id=c366bf379bb1092d995dc3ee85c652cdae1e7867cc61435044d2b9afd2abe1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.",
                "category": "company",
                "datetime": 1782907980,
                "headline": "Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage"
              },
              {
                "id": 140779455,
                "url": "https://finnhub.io/api/news?id=56407b9333027368b50412c86ef772336e29d20a2ca1742b1e6cd59893752407",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role as Co-Founder and Chief Executive Officer of CrossBridge Bio through its acquisition by Eli Lilly. The financing will support advancement of ARTAN Bio's proprietary mutation-specific codon suppression platform toward first-in-human development.",
                "category": "company",
                "datetime": 1782907200,
                "headline": "ARTAN Bio Closes $1 Million Seed Round to Advance its tRNA Platform Toward Human Studies"
              },
              {
                "id": 140781140,
                "url": "https://finnhub.io/api/news?id=8fbbc621a8cd4fb575577ee0790b5cbd4701f3005be419ed0d5f09c427524215",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.2% on an annualized basis producing an average annual return of 16.46%. Currently, Eli Lilly has a market capitalization of $1.06 trillion.",
                "category": "company",
                "datetime": 1782903633,
                "headline": "$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 140778355,
                "url": "https://finnhub.io/api/news?id=f858d150b392e08338495fc19b629f0cc19401be2e64d6cdcf4058b11923aa14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?",
                "category": "company",
                "datetime": 1782899754,
                "headline": "Beyond the GLP-1RA weight loss ceiling"
              },
              {
                "id": 140778356,
                "url": "https://finnhub.io/api/news?id=e6553d626cfe0811c61def0c4c2f6b1045a7f14eba26bbe2795792dcc6cce600",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.",
                "category": "company",
                "datetime": 1782894734,
                "headline": "Eli Lilly and Innovent agree Verzenios commercialisation deal in China"
              },
              {
                "id": 140779009,
                "url": "https://finnhub.io/api/news?id=7e235737e75307f34990d1801b064b293be3163db461302e6a36048a1c483be2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220524615/image_2220524615.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "The July 2026 Top 25 High-Growth Dividend Stocks list targets high-quality companies with strong dividend growth and attractive valuations.",
                "category": "company",
                "datetime": 1782894203,
                "headline": "Top 25 High-Growth Dividend Stocks For July 2026"
              },
              {
                "id": 140775242,
                "url": "https://finnhub.io/api/news?id=02b91b29d4d6866e764fad5d9b5d883e4c856174563540aa0f7ce0aaf8483c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.",
                "category": "company",
                "datetime": 1782851051,
                "headline": "Why Is JNJ Stock Defying The Market’s Daily Mood Swings?"
              },
              {
                "id": 140775243,
                "url": "https://finnhub.io/api/news?id=611b3667755b8e730baafdb8b9807052d6b0e7b93d0f01087df26da9b4877386",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.",
                "category": "company",
                "datetime": 1782849780,
                "headline": "Medicare GLP-1 Bridge Program Will Pay for Novo, Lilly Drugs"
              },
              {
                "id": 140794987,
                "url": "https://finnhub.io/api/news?id=5ec24d697190f1c28757b334eff89bc95cef699b656004472e841785801e1a0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk and Eli Lilly struck a Medicare deal Tuesday that could give their obesity segments a serious boost.",
                "category": "company",
                "datetime": 1782847133,
                "headline": "Medicare Opens the GLP-1 Floodgates for Novo, Eli Lilly"
              },
              {
                "id": 140774479,
                "url": "https://finnhub.io/api/news?id=78e8b5dd1a59f50caffd94f2651b44443b239ce0a607f5daae2fbd722b44d4e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.",
                "category": "company",
                "datetime": 1782845220,
                "headline": "Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease"
              },
              {
                "id": 140781615,
                "url": "https://finnhub.io/api/news?id=a41b497352b243f30385a2d53aefb1bce180e1468e1ef5bef606c5f068d620db",
                "image": "https://image.cnbcfm.com/api/v1/image/108328987-17828552841782855282-46874781825-1080pnbcnews.jpg?v=1782855283&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Angelica Peebles to talk Anthropic's new healthcare offering.",
                "category": "company",
                "datetime": 1782841349,
                "headline": "Anthropic launches Claude Science"
              },
              {
                "id": 140773470,
                "url": "https://finnhub.io/api/news?id=29b707e7552d0a70a8c9ae70a8ce5913e3ad8726016f2c23b7119c1377c3a237",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly transferred mainland China commercialization rights for Verzenio to Innovent Biologics.",
                "category": "company",
                "datetime": 1782838956,
                "headline": "Eli Lilly Hands China Sales Rights for Verzenio to Innovent"
              },
              {
                "id": 140773471,
                "url": "https://finnhub.io/api/news?id=b60fbb2c0ce1fb45c8387013f66392ad1bc0f85028dedac5e289199b0afaea57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...",
                "category": "company",
                "datetime": 1782836340,
                "headline": "Merck, AbbVie probed by US lawmakers over China clinical trials: report"
              },
              {
                "id": 140773472,
                "url": "https://finnhub.io/api/news?id=dd9f3be263efd64a982febd2eb45d8054e1d87167760cd4440f21992ddf440a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The abbreviated week in the market could set the tone for the back half of 2026.",
                "category": "company",
                "datetime": 1782833880,
                "headline": "Pivotal Week Ahead: Warsh's Hawkish Turn, June Jobs Report on Deck"
              },
              {
                "id": 140772789,
                "url": "https://finnhub.io/api/news?id=de3f318bb1515c1dee051c15eb7470cc6fbc1f3e800340946c3b41a4d183288d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.",
                "category": "company",
                "datetime": 1782833505,
                "headline": "Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme"
              },
              {
                "id": 140774085,
                "url": "https://finnhub.io/api/news?id=f82c597c7b0224650e59ddbedd837ca5b0705ff6b4b1e9f677918cb5b2ffc780",
                "image": "",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1782829958,
                "headline": "Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate"
              },
              {
                "id": 140772790,
                "url": "https://finnhub.io/api/news?id=94aa74eb751677e04eddab40996ab91430ca8904551a8a2e394c1da46f66f993",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.",
                "category": "company",
                "datetime": 1782829320,
                "headline": "Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?"
              },
              {
                "id": 140772791,
                "url": "https://finnhub.io/api/news?id=34aec002b32bc63d5f61589ce33fa8bdb4921464c5babb6a2030838a8821994e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Innovent will take over importing, marketing, and distributing Verzenios in mainland China as generic competition looms",
                "category": "company",
                "datetime": 1782828638,
                "headline": "Eli Lilly transfers China rights for Verzenios to Innovent Biologics"
              },
              {
                "id": 140771824,
                "url": "https://finnhub.io/api/news?id=e1dd2417e2816b324b2de38909fb8bb300180f32722f54e7aca1ff37b0527d61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity",
                "category": "company",
                "datetime": 1782826709,
                "headline": "AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity"
              },
              {
                "id": 140771949,
                "url": "https://finnhub.io/api/news?id=fb6daa8c84b48e87501d79d0012f01b3ffe3345db3bf5c818216b8b82335712a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SOUTH SAN FRANCISCO, Calif., June 30, 2026--TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051",
                "category": "company",
                "datetime": 1782824400,
                "headline": "TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051"
              },
              {
                "id": 140771950,
                "url": "https://finnhub.io/api/news?id=083f9e2d2a68b906392076d82dd1f219caf6cb1c7fc1470efd969b151eccb29d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Deal gives Innovent commercialization rights in mainland China.",
                "category": "company",
                "datetime": 1782821696,
                "headline": "Eli Lilly Expands China Cancer Reach"
              },
              {
                "id": 140771951,
                "url": "https://finnhub.io/api/news?id=32d382580a359cbe6d7e25b245ddecba242f967a38fed66cddf7d847d7946668",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "- Proceeds will fund advancement of ARON degrader, FX-111, to proof of concept and preclinical development of ARON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through next phase of growth focused on prostate cancer CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover and develop precision medicines, today announced the closing of",
                "category": "company",
                "datetime": 1782820800,
                "headline": "Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer"
              },
              {
                "id": 140771572,
                "url": "https://finnhub.io/api/news?id=b935258c1075a4fd16e03ae08e3de8772954d64711d60721af0c987486266f27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction",
                "category": "company",
                "datetime": 1782817844,
                "headline": "FDA PreCheck pilot program selects Eli Lilly, Regeneron"
              },
              {
                "id": 140772580,
                "url": "https://finnhub.io/api/news?id=a1dbaf2707146a9b63d62e4d0242f6919ac899d858291284c9391b392a71123b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Motala--Sweden--7-January-2023-Fda-Logo-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.",
                "category": "company",
                "datetime": 1782814640,
                "headline": "Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness"
              },
              {
                "id": 140772368,
                "url": "https://finnhub.io/api/news?id=3baa0b6d8130b52153c4c742a502edc285b76c9502f66aef88dfb9d8fc3d6dd9",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1782813049,
                "headline": "U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials"
              },
              {
                "id": 140774740,
                "url": "https://finnhub.io/api/news?id=bac1556681a38492c41d8ad99cae5880494ce345262ebc615ded85f7f7858fe6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Two-Injectors-Dosing-Pens-For-Subcutaneo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Medicare GLP-1 coverage starts Wednesday. Here’s what patients should know about cost, eligibility and access.",
                "category": "company",
                "datetime": 1782808093,
                "headline": "Getting Wegovy Or Zepbound Through Medicare? Here's What Patients Need To Know Before Coverage Rolls Out Wednesday"
              },
              {
                "id": 140771137,
                "url": "https://finnhub.io/api/news?id=84479ffdcab6081c19c98e41e5559a52d372b160b7cc1f219f95ace9beac9e36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SpaceX recently completed a record IPO.",
                "category": "company",
                "datetime": 1782807720,
                "headline": "5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX"
              },
              {
                "id": 140781616,
                "url": "https://finnhub.io/api/news?id=963e113201613b2c8851be69d4c0c869173d8c74ae1382c1c6b8ad9bd0930f03",
                "image": "https://image.cnbcfm.com/api/v1/image/108328618-17828207261782820723-46866154319-1080pnbcnews.jpg?v=1782820725&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "House Select Committee on China Chairman Rep. John Moolenaar (R-Mich.) joins 'Squawk Box' to discuss the committee's probe into pharmaceutical drug testing in China, the U.S.-China AI race, and more.",
                "category": "company",
                "datetime": 1782806491,
                "headline": "Rep. John Moolenaar on China drug trial probe"
              },
              {
                "id": 140781617,
                "url": "https://finnhub.io/api/news?id=595578358436c02ca69098e100d543c131ea3f3936c4b8b6d4cea2efc2233f2e",
                "image": "https://image.cnbcfm.com/api/v1/image/108326901-1782402782515-gettyimages-2282733148-AFP_B8BN4GJ.jpeg?v=1782405357&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Here are five key things investors need to know to start the trading day.",
                "category": "company",
                "datetime": 1782805099,
                "headline": "SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning Squawk"
              },
              {
                "id": 140770794,
                "url": "https://finnhub.io/api/news?id=f034a1d4005eb11dac136f3e0567ce09b36c8ea64d466de290f5fad4ce74cc69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight loss tailwind isn't about to come to a halt.",
                "category": "company",
                "datetime": 1782804000,
                "headline": "Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years"
              },
              {
                "id": 140781619,
                "url": "https://finnhub.io/api/news?id=291ce5f788bf8dd57f6e9545263698fee9fbfed8374837611199f6ec68f6d288",
                "image": "https://image.cnbcfm.com/api/v1/image/108328219-1782751789876-gettyimages-2279484892-64393_48_ms_4772.jpeg?v=1782751835&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "GLP-1 drugs have remained out of reach for many Americans on Medicare due to their cost. A new pilot program launching July 1 is changing that. CNBC’s Annika Constantino has the details.",
                "category": "company",
                "datetime": 1782795601,
                "headline": "This new Medicare program offers obesity drugs for $50 a month. Here’s what you need to know"
              },
              {
                "id": 140781618,
                "url": "https://finnhub.io/api/news?id=c2b9cf7db5e8e7b511f80cba972d4339f22d420c6b2bd7054751c0b254645eec",
                "image": "https://image.cnbcfm.com/api/v1/image/108139249-17461007952025-05-01t110135z_141929000_rc26x7av6mkm_rtrmadp_0_health-obesity-who.jpeg?v=1746100832&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.",
                "category": "company",
                "datetime": 1782795601,
                "headline": "Medicare will start covering obesity drugs for the first time. Here's what patients should know"
              },
              {
                "id": 140770892,
                "url": "https://finnhub.io/api/news?id=05246e7da56482fd9c0ae977b47c6c3ec2861ee07f3fd46d27d4251486845dee",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2218794567/image_2218794567.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly is leveraging its exceptional cash flow to build an AI-native drug discovery and manufacturing platform. Read why LLY stock is a Buy.",
                "category": "company",
                "datetime": 1782792148,
                "headline": "Forget Weight Loss: Eli Lilly's Real Upside Is As An AI Compounder"
              },
              {
                "id": 140770055,
                "url": "https://finnhub.io/api/news?id=91caaf967e4e00447d29efbb9f75d04a99c1b8a44db04f93d8c2e88d41cfba9c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China:",
                "category": "company",
                "datetime": 1782792000,
                "headline": "Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China"
              },
              {
                "id": 140770030,
                "url": "https://finnhub.io/api/news?id=81ce98efceb6118248cb9b613d0be40760b83b7832377ce78f03489c72a297a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Micron is now 1.9% of the benchmark index in terms of weight.",
                "category": "company",
                "datetime": 1782790814,
                "headline": "MU Stock Caps Best First Half Ever With 4x Surge, Cracks S&P 500’s Top 10: Retail Bulls Want More"
              },
              {
                "id": 140022502,
                "url": "https://finnhub.io/api/news?id=c4b2508893fdf859eedbbcbdca73acab77fea0fe8f3254adf710144e808f6c4b",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1782788830,
                "headline": "Reported Earlier, HUTCHMED And Innovent Secure NDA Review In China For Fruquintinib–Sintilimab In Patients Failing Prior TKI Treatment"
              },
              {
                "id": 140769321,
                "url": "https://finnhub.io/api/news?id=71d4561fdeb6df32b59141316bb4ecaa108f3954e0a39cd00bec2edc34f531ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Given its significant hedge fund backing and attractive upside potential, NVIDIA Corporation (NASDAQ:NVDA) is one of the most promising robotics stocks. NVIDIA Corporation (NASDAQ:NVDA) is extending its physical AI ambitions on two fronts simultaneously, pushing deeper into industrial robotics safety while advancing its push into agentic life sciences. On June 23, 2026, NVIDIA Corporation (NASDAQ:NVDA) […]",
                "category": "company",
                "datetime": 1782785057,
                "headline": "NVIDIA (NVDA) Among The Most Promising Robotics Stocks; Here’s Why"
              },
              {
                "id": 140767824,
                "url": "https://finnhub.io/api/news?id=0c7269fd6125af4ddaf4b43c552b73a8810687b2800e66dd9146bbbc4f6d1075",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.",
                "category": "company",
                "datetime": 1782769503,
                "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know"
              },
              {
                "id": 140765416,
                "url": "https://finnhub.io/api/news?id=95a85c6616a1501f68624ef59ae95118582b4bae62be2a70cc74e23ab2cfc456",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.",
                "category": "company",
                "datetime": 1782758026,
                "headline": "AbbVie Stock Rockets 17% With 5-Day Winning Streak"
              },
              {
                "id": 140765417,
                "url": "https://finnhub.io/api/news?id=54fca79a72ef6ab10f321f3b9a76224d1539a3dba8e92484bc7fdf1e835ee63d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.",
                "category": "company",
                "datetime": 1782754652,
                "headline": "Should You Chase The Breakout In Eli Lilly Stock?"
              },
              {
                "id": 140766531,
                "url": "https://finnhub.io/api/news?id=e9a2d8df8fe3d265cae855305ce25afe0c53a9bb633ad80629a2843f33f5b8a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220268222/image_2220268222.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Sector outlook for 2H 2026: XLK downgraded, XLI/XLU upgraded, XLY/XLC underperform. Click here to read the analysis in detail.",
                "category": "company",
                "datetime": 1782754200,
                "headline": "My S&P 500 Prediction On Sector Outperformers And Underperformers For 2H/2026"
              },
              {
                "id": 140766217,
                "url": "https://finnhub.io/api/news?id=488e3e2c93c13800334fb14b1876f80a9a8aa7c1ac7f6c72ca089bd9f5f3ff34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241146296/image_2241146296.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and growth. Click here to read more.",
                "category": "company",
                "datetime": 1782752400,
                "headline": "Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It"
              },
              {
                "id": 140763997,
                "url": "https://finnhub.io/api/news?id=acfe0005c1f77e002d431991c8fd15ae43e1891dc94af4b3a32bb943821c4723",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?"
              },
              {
                "id": 140763996,
                "url": "https://finnhub.io/api/news?id=f241264e1ae813d3d1334adca34d4c30f747d2ac81b88d7e5865f733236d5d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs"
              },
              {
                "id": 140767078,
                "url": "https://finnhub.io/api/news?id=16a890f2d949d02699e5446ef6360f37c8e0299f410432efe38abbe7227fd3f1",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.cnbc.com/2026/06/29/eli-lilly-regeneron-in-fda-precheck-manufacturing-program.html?&qsearchterm=eli%20lilly",
                "category": "company",
                "datetime": 1782744903,
                "headline": "'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC"
              },
              {
                "id": 140781620,
                "url": "https://finnhub.io/api/news?id=b6f68c2f88eb4507260ba26dbf69e3ee5ebe1e97e15071c48a33ba6ef608e712",
                "image": "https://image.cnbcfm.com/api/v1/image/108203002-17586586832025-09-23t201602z_1200746466_rc2oxgauogov_rtrmadp_0_usa-lilly.jpeg?v=1782769813&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.",
                "category": "company",
                "datetime": 1782744603,
                "headline": "Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities"
              },
              {
                "id": 140762551,
                "url": "https://finnhub.io/api/news?id=97b036c0a0bd67d50a2c6a3f2070fb7724a4dd6463a6edf516fdbbae908fdf80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Nasdaq recorded its fifth straight day of losses on Friday, while the S&P 500 ended marginally lower, with AI-related chip stocks taking a hit, as investors rotated out of major tech stocks and took refuge in defensive assets.",
                "category": "company",
                "datetime": 1782739680,
                "headline": "Stock Market News for Jun 29, 2026"
              },
              {
                "id": 140762552,
                "url": "https://finnhub.io/api/news?id=388fcf6dadc86ecd1512d77453adb904d121387200cd730d5085356763d5d64f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.",
                "category": "company",
                "datetime": 1782739620,
                "headline": "Here's Why Shares of Eli Lilly Hit an All-Time High on Friday"
              },
              {
                "id": 140771952,
                "url": "https://finnhub.io/api/news?id=c4be32442953f971cc08b8efa1ad4f529b6b67416f847037d6baa05b99ef37be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.",
                "category": "company",
                "datetime": 1782739200,
                "headline": "5 Places Investors Can Hide If the AI Trade Keeps Cracking"
              },
              {
                "id": 140763353,
                "url": "https://finnhub.io/api/news?id=1f7f419f3bbad927aef061ca6d26d67e1cd18b1b1b987034a5656bdefd9c12f3",
                "image": "https://image.cnbcfm.com/api/v1/image/108328213-17827514121782751407-46849797479-1080pnbcnews.jpg?v=1782751411&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's \"Halftime Report\" team debate the end of the quarter and discuss their trading strategy heading into the second half of the year.",
                "category": "company",
                "datetime": 1782738106,
                "headline": "'Halftime' traders debate the market setup for the next half of 2026"
              },
              {
                "id": 140761566,
                "url": "https://finnhub.io/api/news?id=50b3a8423c19bf5197bdb785ca5d68222f40cdd10bf5460234517bb284f91695",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1782736215,
                "headline": "Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today"
              },
              {
                "id": 140761567,
                "url": "https://finnhub.io/api/news?id=e4fd842930c69b4cb1219cad2efac884044ac9b9e4bb65154af4b5903dc71e21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
                "category": "company",
                "datetime": 1782733560,
                "headline": "Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?"
              },
              {
                "id": 140761245,
                "url": "https://finnhub.io/api/news?id=47c14cf1e84950a3a28b648c3734658b98b16788d3e9506ece04e8e386776285",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1029203886/image_1029203886.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "TG Therapeutics, Inc. boosts anti-CD20 share as Q1 revenue jumps 69.6% to $204.9M, but overbought signals hint at a near-term pullback. Click for this TGTX update.",
                "category": "company",
                "datetime": 1782723855,
                "headline": "TG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade)"
              },
              {
                "id": 140759882,
                "url": "https://finnhub.io/api/news?id=6314d5e4a4a0c24bb6774fb1a64d0e8db7e109083f268fcd52e2286a11e8846a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level. Recently, on June 25, Leerink analyst David Risinger raised […]",
                "category": "company",
                "datetime": 1782719727,
                "headline": "Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?"
              },
              {
                "id": 140757924,
                "url": "https://finnhub.io/api/news?id=729a2c31b9f4a6613a413c8aee3ccaec056aee19ad828a7cd2b5341438f3325e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr. Lloyd Klickstein as Scientific Advisor for Immunology.",
                "category": "company",
                "datetime": 1782696420,
                "headline": "Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology"
              },
              {
                "id": 140757296,
                "url": "https://finnhub.io/api/news?id=ce6af60991a8b0d627792b7e3d525c957e6d8d5bd78a906834ac9f40afe5ffa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The U.S. and Iran reportedly have agreed to halt tit-for-tat attacks. Tesla sales and the June jobs report on are on tap.",
                "category": "company",
                "datetime": 1782690165,
                "headline": "Dow Jones Futures Rise On U.S.-Iran News; Market At Tipping Point"
              },
              {
                "id": 140756650,
                "url": "https://finnhub.io/api/news?id=7c5df493acb477f56491149794859fbf4f25325b6da70f3861e014bf8f873ed9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027. Executive Vice President Patrik Jonsson said the company will start targeting patients paying […]",
                "category": "company",
                "datetime": 1782676668,
                "headline": "Is Eli Lilly and Company (LLY) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?"
              },
              {
                "id": 140754949,
                "url": "https://finnhub.io/api/news?id=3e5599853a9c4dbbcf68ee065dda2d530709689c69fcd984f2cce08c9ac7965a",
                "image": "https://image.cnbcfm.com/api/v1/image/108327550-1782492280306-gettyimages-2278151752-dsc00398.jpeg?v=1782492397&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Demand for whey protein is off the charts as American diet trends change and GLP-1s boom, and the dairy industry is struggling to produce enough.",
                "category": "company",
                "datetime": 1782644731,
                "headline": "America can't get enough of protein. The dairy industry can't keep up"
              },
              {
                "id": 140754956,
                "url": "https://finnhub.io/api/news?id=5c331015c13885663587ad1ccc4ea91905820b7042264ca4eb59df742b3639b1",
                "image": "https://image.cnbcfm.com/api/v1/image/106340566-1579197686151gettyimages-172600009.jpeg?v=1782479781&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.",
                "category": "company",
                "datetime": 1782633601,
                "headline": "Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet"
              },
              {
                "id": 140753382,
                "url": "https://finnhub.io/api/news?id=32db7e2ecdb996c42e47ecaa7c60502bc045677130c21d2bbf26755ffc554e1a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217097273/image_2217097273.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly stock surged 7% as healthcare rallies; explore its oncology & neuroscience catalysts, risks from price cuts, and 2026 upside—Click for more on LLY stock.",
                "category": "company",
                "datetime": 1782629424,
                "headline": "Why Eli Lilly Gained 7% On Friday"
              },
              {
                "id": 140748166,
                "url": "https://finnhub.io/api/news?id=fc079b85ed59e2ec2b354a1e6fc75a1ec4655500cc7c15c0c15f6f1c20c6737c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management […]",
                "category": "company",
                "datetime": 1782588092,
                "headline": "Eli Lilly (LLY) and BioArctic AB Enter into Research and Collaboration Agreement"
              },
              {
                "id": 140748167,
                "url": "https://finnhub.io/api/news?id=0ff6346897140395f192ca5cf2c77f410394ef667635e7433763b5a1b0efeca5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119 and maintained an Outperform rating on the shares. In a separate development, […]",
                "category": "company",
                "datetime": 1782585388,
                "headline": "Here’s What the Street Thinks About Eli Lilly and Company (LLY)"
              },
              {
                "id": 140745801,
                "url": "https://finnhub.io/api/news?id=5a5136166e91d7b2cbf2801e022b9737036ee677c337b1146fce4b396b26ec46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's cancer drug Jaypirca received a positive opinion from the European Medicines Agency regarding its use in chronic lymphocytic leukemia. The opinion supports potential use of Jaypirca across all lines of therapy for CLL in Europe. The recommendation is based on Phase 3 clinical trial data and now moves to European Commission review. Eli Lilly (NYSE:LLY) is best known recently for its GLP-1 portfolio, and oncology remains an important part of the business. The EMA's positive view...",
                "category": "company",
                "datetime": 1782562086,
                "headline": "Eli Lilly (LLY) Wins EMA Backing For Jaypirca In Chronic Lymphocytic Leukemia"
              },
              {
                "id": 140745802,
                "url": "https://finnhub.io/api/news?id=b30dc21b3b7de4f63f7067e3513aa02e8fc7d4d9214efbffd33ca5fac2f5eef3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and EZ Corp. lead stocks to watch near buy points this week as investors seek shelter in defensive growth names.  The relative strength lines of all top five stocks near buy points are making new highs or near highs.  The strong RS lines, which track performance vs. the S&P 500, are especially bullish given the overall uncertain stock market.",
                "category": "company",
                "datetime": 1782561635,
                "headline": "Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally Rotates"
              },
              {
                "id": 140745269,
                "url": "https://finnhub.io/api/news?id=6047475b0e68c13aab5e5bd802b75f2a79893d8384287a4ac04d1a8afab5b1e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL […]",
                "category": "company",
                "datetime": 1782559308,
                "headline": "Eli Lilly (LLY) Announces Positive Phase 3 Results for Jaypirca Combination in Relapsed CLL/SLL"
              },
              {
                "id": 140741461,
                "url": "https://finnhub.io/api/news?id=2b0fb60af9a42b5beea966409f60b5392641b4c56407494a18c94191d30f21e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The pharma titan is expanding into new markets.",
                "category": "company",
                "datetime": 1782516843,
                "headline": "Why Eli Lilly Stock Jumped to a New All-Time High Today"
              },
              {
                "id": 140741495,
                "url": "https://finnhub.io/api/news?id=c813f38b390c2f9db574fc3157e467f875f5a60ca08665b576c32768cd10b770",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's committee for human medicines backed its cancer drug, Jaypirca, and the company's popular weight-loss treatments were set for inclusion in a new Medicare program.",
                "category": "company",
                "datetime": 1782512665,
                "headline": "Why Is Eli Lilly (LLY) Stock Soaring Today"
              },
              {
                "id": 140740423,
                "url": "https://finnhub.io/api/news?id=b9016c046004f47d1a75815c7b7b79f56d0fc74ed894d2cae637a664dbc97d85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Here's what investors should do amid the stock market's divergent signals. Eli Lilly is strong while Tesla EV sales loom.",
                "category": "company",
                "datetime": 1782507330,
                "headline": "Dow Jones Futures: Market At Tipping Point, Here's What To Do. Eli Lilly Soars, Tesla On Tap."
              },
              {
                "id": 140738838,
                "url": "https://finnhub.io/api/news?id=e91c2b0f4ac08ab15ff4b8aa3a67fdbce3e4806d88c2ece3ecebfbb37b44459a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.",
                "category": "company",
                "datetime": 1782500701,
                "headline": "Discover which S&P500 stocks are making waves on Friday."
              },
              {
                "id": 140737991,
                "url": "https://finnhub.io/api/news?id=4f1f92e9bfd556033ca1e9a7a947069be8194bd99d29c4f03bd80a254adeb6e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly, AbbVie and J&J extend winning streaks.",
                "category": "company",
                "datetime": 1782496164,
                "headline": "Lilly, J&J and AbbVie Hit New Highs"
              },
              {
                "id": 140737891,
                "url": "https://finnhub.io/api/news?id=7e11a2a8ab37d8e1e86b26bc80c226a79bdb70d0eec0a50229ae24976c1591c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The smartphone could be a thing of the past if Snap has its way. But at $2,195, it could be a tall order to sell Specs to consumers, even if they were stylish.",
                "category": "company",
                "datetime": 1782494598,
                "headline": "Snap’s Specs Gamble"
              },
              {
                "id": 140746796,
                "url": "https://finnhub.io/api/news?id=fe15595f4953f27cc4b58c74d5c83ff2d2864a24e30ace17bb82dd2bdc1827df",
                "image": "https://image.cnbcfm.com/api/v1/image/108327725-17825072231782507209-46792477115-1080pnbcnews.jpg?v=1782507222&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.",
                "category": "company",
                "datetime": 1782493286,
                "headline": "Why BMO's Siegerman says Merck is a top healthcare stock pick"
              },
              {
                "id": 140737076,
                "url": "https://finnhub.io/api/news?id=c1a676c37531c97d9038d97178e0db4705207ed0c4764295496954ccbc7639d4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1782491701,
                "headline": "Friday's session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 140737993,
                "url": "https://finnhub.io/api/news?id=4ec7a0224ab0405979874fb3b438152890cd9bb8fada3b210159c9b7b2acaaad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.",
                "category": "company",
                "datetime": 1782489808,
                "headline": "AbbVie Stock's Growth Story Has One Question Mark"
              },
              {
                "id": 140736678,
                "url": "https://finnhub.io/api/news?id=3038664d97ac7d1daf0c10601b93304de255e6d67a4da96d5a72fbffbd13b631",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.",
                "category": "company",
                "datetime": 1782489660,
                "headline": "Why Moderna Stock Is Soaring and Leading the S&P 500 Today"
              },
              {
                "id": 140736419,
                "url": "https://finnhub.io/api/news?id=6e646450267a59ab1615f9f48a55dfc084b44f94ece0d811c00231386775fc1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.",
                "category": "company",
                "datetime": 1782487602,
                "headline": "Nike Stock Languishes, But Looming Earnings Report Fuels Turnaround Optimism"
              },
              {
                "id": 140736420,
                "url": "https://finnhub.io/api/news?id=784bcfda55729331b9b815af9b95f90ace15fb3796f4f28b1ee92a1b7c6b6ed8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Trump’s children have been buying and selling stock on his behalf while he’s in office, posing a legal quagmire.",
                "category": "company",
                "datetime": 1782487329,
                "headline": "Trump name-dropped Nokia and Eli Lilly in a Pennsylvania speech. Here's what happened to 5 other stocks he singled out"
              },
              {
                "id": 140736421,
                "url": "https://finnhub.io/api/news?id=b9a0b9da55fb70fd616ac795d9b27549c0ca6f38d6b1f0f28b9a0548a840ba9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The...",
                "category": "company",
                "datetime": 1782485760,
                "headline": "Eli Lilly shares rise after EU panel backs expanded use of Jaypirca"
              },
              {
                "id": 140738319,
                "url": "https://finnhub.io/api/news?id=836bcfe7c2e7088a1d512d316d935002acddd7e4f3d6233f67bdf2745c49da75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160887573/image_1160887573.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Micron goes volatile on great news, SpaceX the bellwether and Fed interest rate commentary.",
                "category": "company",
                "datetime": 1782483240,
                "headline": "Wall Street Roundup: What Isn't Priced In?"
              },
              {
                "id": 140736422,
                "url": "https://finnhub.io/api/news?id=0670f579dfac7d1206e11eea64d3f7d776cb1650aed7eb2cdea372d7d40188d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab drug discovery platform. This collaboration ties Charles River more closely into Lilly’s Catalyze360 ecosystem, potentially deepening its role in data-rich, AI-enhanced preclinical research workflows. We’ll now examine how Charles River’s deeper integration into Lilly’s AI-driven...",
                "category": "company",
                "datetime": 1782482876,
                "headline": "Is Charles River (CRL) Quietly Redefining Its Moat Through Lilly’s AI-Driven TuneLab Collaboration?"
              },
              {
                "id": 140737794,
                "url": "https://finnhub.io/api/news?id=b7075843871960b8dfef8a6e1135fd76a2f5eb40182cc34afd039e3a4c54ce3b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406728342/image_1406728342.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly hits a 52-week high on retatrutide, Mounjaro & Kisunla growth, but valuation and Omvoh demand prompt a Hold rating. Click for this LLY update.",
                "category": "company",
                "datetime": 1782481376,
                "headline": "Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)"
              },
              {
                "id": 140737291,
                "url": "https://finnhub.io/api/news?id=f967565bde51a202a27c29a0137a0c215d2512f7031b456cec9015d4e7b99a56",
                "image": "https://image.cnbcfm.com/api/v1/image/108222303-1762434766877-gettyimages-2235744008-CANADA_BIOMANUFACTURING.jpeg?v=1782492668&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1782478763,
                "headline": "Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more"
              },
              {
                "id": 140737078,
                "url": "https://finnhub.io/api/news?id=8a0ee8ed09b1c9cc93901aba4ae3ce74cfb2c6a2d282cd515cdd310326975c69",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257962304/image_1257962304.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk A/S outlook: 2026 guidance warns revenue/profit declines as GLP-1 competition, pricing pressure & patent risks rise. Click for this NVO update.",
                "category": "company",
                "datetime": 1782478606,
                "headline": "Novo Nordisk: 3 Key Reasons The 'Buy The Dip' Thesis Is Flawed"
              },
              {
                "id": 140736423,
                "url": "https://finnhub.io/api/news?id=e1eab1fbff0591622582456369b3e19f8e6fa884061d0b49354e44dae6555244",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.",
                "category": "company",
                "datetime": 1782474780,
                "headline": "FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services"
              },
              {
                "id": 140734580,
                "url": "https://finnhub.io/api/news?id=f2739b015eb855b06aaf19cce265f12fc3dffd2e41df80353c90ceed7b116169",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.",
                "category": "company",
                "datetime": 1782474001,
                "headline": "Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value?"
              },
              {
                "id": 140734581,
                "url": "https://finnhub.io/api/news?id=4a4c63e05d2585fa92f9a744fd499153a8a9b4cc554880ecdf0cb5b5efd5fba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment. Following this positive opinion, the application is now referred to the European Commission f",
                "category": "company",
                "datetime": 1782472560,
                "headline": "Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy"
              },
              {
                "id": 140734582,
                "url": "https://finnhub.io/api/news?id=783559ea51e284287c75f8f39c295e81180a0f625ce3e3c45626346627b15f6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Amid the debut of positive Phase I data, the biotech will push its lead asset further down the clinical pipeline in endometriosis and pattern hair loss.",
                "category": "company",
                "datetime": 1782469636,
                "headline": "Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy"
              },
              {
                "id": 140736206,
                "url": "https://finnhub.io/api/news?id=cdc9a33779d720a37b959998e39d27a423105e6862becd0d2ae9974a8fbfd7f2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/26/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc (NASDAQ: FCEL) up 17.6%, BitVentures Limited (NASDAQ: BVC) up 14.1%, and ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) up 10.3% after receiving a positive recommendation for a market authorization in Europe. ",
                "category": "company",
                "datetime": 1782469136,
                "headline": "Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday"
              },
              {
                "id": 140737995,
                "url": "https://finnhub.io/api/news?id=3f9c8f2a8b88e3298d1e984a23c40896e1c18214d4f917f3df1480de259226b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.",
                "category": "company",
                "datetime": 1782467204,
                "headline": "Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda"
              },
              {
                "id": 140734044,
                "url": "https://finnhub.io/api/news?id=7461902ddcadc250b778ba778c03a310a60610715444e944f83a304150ba4876",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multiple ascending dose stage. On the heels of these results, Absci also completed a roughly US$100.00 million follow-on equity offering backed by Eli Lilly & Company and other institutional investors, underscoring external confidence in the ABS-201 program...",
                "category": "company",
                "datetime": 1782461214,
                "headline": "Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?"
              },
              {
                "id": 140734045,
                "url": "https://finnhub.io/api/news?id=38ab79d79607aa083ff9b8b1b65fe7dced4541cd2820ee7cdc2642fb574296d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks for beginners to buy now. On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, aiming to advance the development of orexin receptor 2 agonists. This new class of medicine is designed to treat narcolepsy and other sleep-wake disorders by targeting the brain’s […]",
                "category": "company",
                "datetime": 1782461200,
                "headline": "Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists"
              },
              {
                "id": 140734425,
                "url": "https://finnhub.io/api/news?id=646303d80cfd74015bd333109eec3ebdf984fa67010398d6dce2f68838a5f613",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2243155532/image_2243155532.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Cabaletta Bio (CABA) CAR-T for autoimmune disease: EULAR 2026 data, $2.90 entry, $150M raise, 2H27 BLA path, and upside potential—read now.",
                "category": "company",
                "datetime": 1782459047,
                "headline": "Cabaletta Bio: The Market Sold The EULAR News, I'm Buying"
              },
              {
                "id": 140736207,
                "url": "https://finnhub.io/api/news?id=3d8b7bed42fc5493b02e72a70cec8a5aabe8f345d78c2fe94ba151ec7de700cb",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical",
                "category": "company",
                "datetime": 1782458493,
                "headline": "Eli Lilly Gets EMA CHMP Positive Opinion For Jaypirca In Chronic Lymphocytic Leukemia; Application Referred To European Commission For Final Action"
              },
              {
                "id": 140737449,
                "url": "https://finnhub.io/api/news?id=898a90962632ed83b9ba07f006d83e69b2b882024474de3ecacbe1dac778222d",
                "image": "https://image.cnbcfm.com/api/v1/image/108327074-1782417569804-gettyimages-2261992594-hhhtimelessfeminitygetty2025hhh221.jpeg?v=1782417706&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Estrogen patches are in short supply as demand for menopause treatments skyrockets, and it could take at least a year for manufacturers to catch up.",
                "category": "company",
                "datetime": 1782457201,
                "headline": "Estrogen patches are hard to find, and it may not be resolved any time soon"
              },
              {
                "id": 140735323,
                "url": "https://finnhub.io/api/news?id=87912e5b95371e6cd332bbd7bc802e8bf0e0e359277309e9fee0572313d60e3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The pharma company, the first to use generative AI to develop a drug that reached clinical trials, is betting longevity treatments will fuel its next phase of growth.",
                "category": "company",
                "datetime": 1782456420,
                "headline": "InSilico Is on a Mission: Be No. 1 in China, Create ‘God Drug’ With AI"
              },
              {
                "id": 140732204,
                "url": "https://finnhub.io/api/news?id=dae16bc4f4d0a398a07124fdb817b4b84fcb53692dc0aa84cb23e1c9c885feeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Nancy Pelosi Stock Tracker account on Wednesday spotlighted Eli Lilly & Co. and Nokia Oyj after President Donald Trump praised the companies’ U.S. investment plans during a rally in Pennsylvania. ‘Keep An Eye’ Trump said Eli Lilly will invest...",
                "category": "company",
                "datetime": 1782441066,
                "headline": "Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’"
              },
              {
                "id": 140737450,
                "url": "https://finnhub.io/api/news?id=647526d9eaff5708330f9872a6264ce8a5067d661cc27a4dce2c6fee73926720",
                "image": "https://image.cnbcfm.com/api/v1/image/108327432-1782483970820-Traders-Photo-20260626-KK-PRESS-001.jpg?v=1782484337&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "OpenAI is reportedly considering delaying its IPO and as a sell-off in tech gathered pace.",
                "category": "company",
                "datetime": 1782410579,
                "headline": "S&P 500 heads for losing week, chip stocks add to their losses on Friday: Live updates"
              },
              {
                "id": 140725554,
                "url": "https://finnhub.io/api/news?id=e23269ab3cc9a043432fdc41d29cf9c823f0156c80e4074890dff10f6e58822a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is no longer the front-runner, but it's not out of the running, either.",
                "category": "company",
                "datetime": 1782401880,
                "headline": "An Analyst Just Declared Eli Lilly the \"Clear Winner\" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?"
              },
              {
                "id": 140725623,
                "url": "https://finnhub.io/api/news?id=e606089c9c3579d1423532696d17e514b271cb1157e712fb21beaaf1e2d2995c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Major employers and even governments have begun to address concerns of AI-driven job losses, according to a new report by the Wall Street Journal. Morning Brief Host Julie Hyman is joined by Yahoo Finance Tech Editor Dan Howley and Epistrophy Capital Research chief market strategist Cory Johnson to take a closer look at this headline.",
                "category": "company",
                "datetime": 1782397800,
                "headline": "Employers, governments join forces to address AI job loss concerns"
              },
              {
                "id": 140725667,
                "url": "https://finnhub.io/api/news?id=acaefe59bfd64ff1d0fa4aedb01bfb2e7fb5968db010d537b4dacfb1012951d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.",
                "category": "company",
                "datetime": 1782395820,
                "headline": "VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug"
              },
              {
                "id": 140725603,
                "url": "https://finnhub.io/api/news?id=7eed288d9717bb09c3523d4b46516d2e4ac00b07a3dacab5765a363039e56cc9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a",
                "category": "company",
                "datetime": 1782394800,
                "headline": "Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside"
              },
              {
                "id": 140726458,
                "url": "https://finnhub.io/api/news?id=760aa3bb75cb55185d1ad9b8997324a47603aeac7746264f37945ce55241212a",
                "image": "https://image.cnbcfm.com/api/v1/image/108326924-17824048051782404800-46767576407-1080pnbcnews.jpg?v=1782404804&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The Investment Committee debate Micron's rise and what it means for the rotation and how you should trade it. Jim Lebenthal, Chief Market Strategist at Cerity Partners, joins CNBC's \"Halftime Report\" to explain why he's buying it here.",
                "category": "company",
                "datetime": 1782392702,
                "headline": "Micron surges to new highs on blockbuster earnings: Jim Lebenthal buys the stock"
              },
              {
                "id": 140727769,
                "url": "https://finnhub.io/api/news?id=80b12b656bc2c77275055ab45e1c71439d242f3fd22e634fb1d25175611c9e25",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Leerink Partners  analyst David Risinger   maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1119 to $1232.",
                "category": "company",
                "datetime": 1782389547,
                "headline": "Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1232"
              },
              {
                "id": 140723886,
                "url": "https://finnhub.io/api/news?id=343a74422c34a3b0ee7a7a7a7adab176b7a5f566da9c1f234d4dc3784ce91851",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced additional details regarding the Medicare GLP-1 Bridge* program taking effect July 1, 2026. Under the program, Medicare Part D patients may be able to access Foundayo (orforglipron) or Zepbound (tirzepatide) KwikPen for single-patient-use for weight management. The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be able to broadly receive coverage for a GLP-1 for overweight or obesity.1 We believe this",
                "category": "company",
                "datetime": 1782384300,
                "headline": "What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management"
              },
              {
                "id": 140723887,
                "url": "https://finnhub.io/api/news?id=b71e182a4775ae3419318cd2c6f2da5392cada00826d69eeb6736d9893fb16ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross pr",
                "category": "company",
                "datetime": 1782383700,
                "headline": "ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement"
              },
              {
                "id": 140726620,
                "url": "https://finnhub.io/api/news?id=11b7827ebe98459da5a2b72e31c52f7b0c296e8b5daa03ef260fc359c2264f0b",
                "image": "https://image.cnbcfm.com/api/v1/image/108326818-17823960221782396020-46765360731-1080pnbcnews.jpg?v=1782396021&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s Angelica Peebles reports on the latest news.",
                "category": "company",
                "datetime": 1782381833,
                "headline": "Medicare to launch GLP-1s for $50: Here's what to know"
              },
              {
                "id": 140727770,
                "url": "https://finnhub.io/api/news?id=6a96edad9d053042d399435d27b8c9dd79caf4ce2593650ca340e3328415eb70",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/25/Collapsing-Dna-Molecules-On-A-Blurred-Ba.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.",
                "category": "company",
                "datetime": 1782381394,
                "headline": "Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success"
              },
              {
                "id": 140723103,
                "url": "https://finnhub.io/api/news?id=c0811b0d20c04b967ff0011e23ceddaf18e75ddefa9b775a668f1f54d44e7152",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Discover how Eli Lilly (LLY) combines explosive growth and strong technical setup. A deep-dive into this top-rated stock's breakout potential.",
                "category": "company",
                "datetime": 1782377435,
                "headline": "Eli Lilly & Co (NYSE:LLY) Screens as a Top Growth Stock with a Strong Technical Breakout Setup"
              },
              {
                "id": 140725194,
                "url": "https://finnhub.io/api/news?id=083ff9e58125d4297d822ac647f1b28da6a45216fddf82805025d03ed7e02ecb",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be able to broadly receive coverage for a GLP-1 for overweight or obesity.1 We believe this is a milestone that reflects",
                "category": "company",
                "datetime": 1782370290,
                "headline": "Eli Lilly Announces Additional Details On Medicare GLP-1 Bridge Program From July 1; Medicare Part D Patients May Be Able To Access Foundayo Or Zepbound Kwikpen For Single-Patient-Use For Weight Management"
              },
              {
                "id": 140727772,
                "url": "https://finnhub.io/api/news?id=672d2b76c01c2809662f6bc53d47649295f9ec58f5fccbc6016d92cdc950a9af",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology",
                "category": "company",
                "datetime": 1782369577,
                "headline": "ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Total Gross Proceeds Of ~$50M; Also Enters Private Placement With Lilly For ~5.1M Shares At Same Offer Price"
              },
              {
                "id": 140722827,
                "url": "https://finnhub.io/api/news?id=9d9dcf6eb6e5fc6bdbe02f891a38bb21d3bde4b48a913b0a2e50e7fd8c2a3b98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.",
                "category": "company",
                "datetime": 1782368400,
                "headline": "The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch"
              },
              {
                "id": 140727773,
                "url": "https://finnhub.io/api/news?id=03a49df4f9f2bd0d8e280740e8bf8d4707548f5679a56c98d41144c19e71ca49",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "-Reuters",
                "category": "company",
                "datetime": 1782363017,
                "headline": "Eli Lilly India Launches Tanstrive (Selpercatinib) In India For Locally Advanced Or Metastatic RET-Altered Solid Tumours"
              },
              {
                "id": 140721975,
                "url": "https://finnhub.io/api/news?id=c90c6b61e36faf87471630f40d3a6bbafdeb70ac4a314511b5af3536d1c1db92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its weight-loss pill in Europe and the UK in the second half of 2026 or early 2027. The company plans to target the out-of-pocket […]",
                "category": "company",
                "datetime": 1782361002,
                "headline": "Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors"
              },
              {
                "id": 140721311,
                "url": "https://finnhub.io/api/news?id=d98eb017c573ae0e82f7929c03434a37d7d03af6b9a177ccb65b4f25c2c8f1df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones for Abbisko and up to US$770 million for BioArctic, alongside royalties on any future product sales. These alliances, paired with Lilly’s ongoing advances in obesity, oncology, and neurodegeneration programs, underline how external partnerships are being used to broaden its pipeline beyond its...",
                "category": "company",
                "datetime": 1782350107,
                "headline": "The Bull Case For Eli Lilly (LLY) Could Change Following New Multi‑Target R&D Alliances With Biotechs"
              },
              {
                "id": 140726621,
                "url": "https://finnhub.io/api/news?id=31b547d8034abe20917600d1cf3d07fbe8d05a043ca075164f4bd308b738a68f",
                "image": "https://image.cnbcfm.com/api/v1/image/108325900-1782272006888-gettyimages-2282099413-AFP_B7T23K6.jpeg?v=1782272068&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Pakistan's efforts to bring an end to the conflict in the Middle East are driven by the need to avoid a spillover across its borders.",
                "category": "company",
                "datetime": 1782344142,
                "headline": "Iran's neighbor, U.S. ally: What Pakistan gains from being a peacemaker"
              },
              {
                "id": 140723310,
                "url": "https://finnhub.io/api/news?id=ec4f24d547434b9f2f5ee029b507be1e724a0f93a73ba359bafc761ed9f03ea4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- At the Hirslanden clinic overlooking Switzerland’s picturesque Lake Lucerne, prostate cancer patient Jörg Pegelow lies on a reclining chair as a doctor wearing two sets of gloves — one made with lead — injects a saline solution laced with a radioactive drug into a vein in his arm.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapOracle Cut 21,000 Jobs in 12 Months, Says AI Replaced",
                "category": "company",
                "datetime": 1782334817,
                "headline": "A $30 Billion Cancer Breakthrough Is Under Threat From Global Conflicts"
              },
              {
                "id": 140718321,
                "url": "https://finnhub.io/api/news?id=4c7ea48b5a2ff249bad7fdae0d697c52b2093ed9809ab2a481f9a9c00ab49b23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Absci Corporation said that its drug ABS-201 was well-tolerated and showed a long-lasting presence in the body in a clinical trial.",
                "category": "company",
                "datetime": 1782330902,
                "headline": "ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise"
              },
              {
                "id": 140717005,
                "url": "https://finnhub.io/api/news?id=3f59a4c983b77042aa9b5c7b418ca5680832404b8328b939e755f4f4f4ef0e61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.",
                "category": "company",
                "datetime": 1782329550,
                "headline": "The Number That Could Test AbbVie Stock"
              },
              {
                "id": 140717006,
                "url": "https://finnhub.io/api/news?id=da9777eae917ebc72757f3d43721e42f0531becf4d27de3d6fdc76687f5d650a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% a",
                "category": "company",
                "datetime": 1782329529,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 140717007,
                "url": "https://finnhub.io/api/news?id=4f799bad3207098a2d3be2b8d6a8d197842d01999348d8fb1f131a0fbf5659e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to its board and a price target increase from Barclays.",
                "category": "company",
                "datetime": 1782327385,
                "headline": "Why Illumina (ILMN) Stock Is Trading Up Today"
              },
              {
                "id": 140717977,
                "url": "https://finnhub.io/api/news?id=21c9c5e2db956c631e74b09e0f7a5a86c134789aa44268ab124f73d8023b890b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483865745/image_1483865745.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "BioAge Labs (BIOA) overview: BGE-102 oral NLRP3 inhibitor shows strong Phase 1 hsCRP/IL-6 drops; $390M cash funds to 2029. Read the full analysis here.",
                "category": "company",
                "datetime": 1782321094,
                "headline": "BioAge Labs: Developing A 'Pipeline In A Pill'"
              },
              {
                "id": 140716996,
                "url": "https://finnhub.io/api/news?id=424aec55c7f93860627389024d3bcc141f93741f5ddacf8ae49995cb967599a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217849566/image_2217849566.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Absci Corporation jumps 30% on $100M equity raise with Eli Lilly. It recently reported promising Phase 1 safety & PK data. Click for an updated look at ABSI stock.",
                "category": "company",
                "datetime": 1782316298,
                "headline": "Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain"
              },
              {
                "id": 140715726,
                "url": "https://finnhub.io/api/news?id=78da2f6c877b62c75671f8deb87cbea647bef022ac22fc266def1c86b79f1812",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Abridge CEO Dr Shiv Rao joins Ashley Mastronardi on NYSE Live to discuss his new parnetships with Nvidia and Eli Lilly",
                "category": "company",
                "datetime": 1782314165,
                "headline": "Abridge CEO Dr. Shiv Rao Elaborates on New Partnerships with Eli Lilly + Nvidia"
              },
              {
                "id": 140712837,
                "url": "https://finnhub.io/api/news?id=e1b3cc7c79dcad8fe6d846b19a9771d7515ce8ce9bd2936b8efb2aca9126be5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Eli Lilly and Company (NYSE:LLY) is one of the best weight loss drugs on this list. TheFly reported on June 16 that LLY completed the acquisition of 4E Therapeutics, a neuroscience biotechnology company based in Austin, Texas. The acquired firm […]",
                "category": "company",
                "datetime": 1782307590,
                "headline": "Is Eli Lilly and Company (LLY) Strengthening Its Pain Management Strategy With New Biotech Acquisition?"
              },
              {
                "id": 140713986,
                "url": "https://finnhub.io/api/news?id=6b2d5bb04fcbf51ab82f11b501253c8b8d69b6e7d698de88c929d248f98e45a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.",
                "category": "company",
                "datetime": 1782305940,
                "headline": "LLY or PFE: Which Drugmaker Offers the Stronger Growth Story?"
              },
              {
                "id": 140712838,
                "url": "https://finnhub.io/api/news?id=4215527483c1ecbc16ffd1cb4bfd9e72825dadccb16cc74c34286b7add539be9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.",
                "category": "company",
                "datetime": 1782305700,
                "headline": "NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare"
              },
              {
                "id": 140712839,
                "url": "https://finnhub.io/api/news?id=d3749f5568b6e3c216e73ea1d4cff2a82ac7c64793deddc26dd6cd747d2f0778",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders.",
                "category": "company",
                "datetime": 1782305100,
                "headline": "Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders"
              },
              {
                "id": 140712174,
                "url": "https://finnhub.io/api/news?id=f49462edaffad3b7a0f1d57a2a66c4c64fa5cf073166e4c3021c4563abab522c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This partnership marks another addition to the growing list of high-profile collaborations between the consumer health and life science sectors.",
                "category": "company",
                "datetime": 1782300877,
                "headline": "ŌURA and Lilly join forces to harmonise drug-wearable obesity care"
              },
              {
                "id": 140716099,
                "url": "https://finnhub.io/api/news?id=49bc0275ba15ec7784bc4148be753cba1de2967195fd321593f8c53e1cf732c4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/24/Eli-Lilly-and-Company.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally.",
                "category": "company",
                "datetime": 1782299508,
                "headline": "Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact"
              },
              {
                "id": 140712175,
                "url": "https://finnhub.io/api/news?id=7bfdb1a8211f63d818c82b3ad8b6d84326a4e32b03e1821ddbd7dd3bf4259e56",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the pricing of",
                "category": "company",
                "datetime": 1782297300,
                "headline": "Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors"
              },
              {
                "id": 140712176,
                "url": "https://finnhub.io/api/news?id=995c2658d83e8a3092c4b242e8cbaf6a21c1893bfa2bf7553159a15389668ee8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for",
                "category": "company",
                "datetime": 1782296346,
                "headline": "Market Chatter: Eli Lilly, Bayer Back US Campaign to Increase Drug Prices in Europe"
              },
              {
                "id": 140712840,
                "url": "https://finnhub.io/api/news?id=19a54da9a9a1d56cc958a53511604f988ed18f0e83a5e9034701acaf85612729",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.",
                "category": "company",
                "datetime": 1782291600,
                "headline": "Recent pharma exec shake-ups signal strategic shifts"
              },
              {
                "id": 140716100,
                "url": "https://finnhub.io/api/news?id=f97ddc9ec138daaca1dd6fab36418d42d848bfccf14e0e1333ad4fba14ffa92c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.reuters.com/legal/litigation/china-approval-eli-lilly-glp-1-pill-come-soon-2026-executive-says-2026-06-24/",
                "category": "company",
                "datetime": 1782290617,
                "headline": "Reported Earlier: 'China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says' - Reuters"
              },
              {
                "id": 140711652,
                "url": "https://finnhub.io/api/news?id=715b1f16fe7bb8c9cd178826cbdabb1821313cba3291961975e3f13deddff872",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "IBB, Novartis, Pfizer and Eli Lilly's have been highlighted in this Investment Ideas article.",
                "category": "company",
                "datetime": 1782289680,
                "headline": "Zacks Investment Ideas feature highlights: IBB, Novartis, Pfizer and Eli Lilly's"
              },
              {
                "id": 140713987,
                "url": "https://finnhub.io/api/news?id=bae5261894a04fe7e332846c8d40423d0b4a21e0d58646988c28a073a6e2a740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA struck a “build-to-buy” deal.",
                "category": "company",
                "datetime": 1782288720,
                "headline": "Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor"
              },
              {
                "id": 140716069,
                "url": "https://finnhub.io/api/news?id=3e6e5615131dfe4fb071349053919a7dfda27eea767b36ab210d1abf7660a743",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/24/Two-Injectors-Dosing-Pens-For-Subcutaneo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide through an FDA program.",
                "category": "company",
                "datetime": 1782284187,
                "headline": "White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President'"
              },
              {
                "id": 140714544,
                "url": "https://finnhub.io/api/news?id=fa5d4616e06e6ef694d837e24b09ae7d899e9799ce6f2e31449c71d0bed066f3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/24/Businessmen-Investor-Stock-Market-Value-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Coatue founder Philippe Laffont redefines the Mag 7 into a trillion-dollar "Mag 12," adding non-tech giants like Berkshire and Eli Lilly.",
                "category": "company",
                "datetime": 1782271995,
                "headline": "Forget The Magnificent 7 And MANGOS—Billionaire Philippe Laffont Adds These Two 'Non-Tech' Giants To His New 'Mag 12'"
              },
              {
                "id": 140709912,
                "url": "https://finnhub.io/api/news?id=5da5cfe25e2b9295e8c80ace3f944fcf610f8a53a43d262d7e2aa9f6d816699e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Trump said the new “state-of-the-art” facility would create over 1,000 jobs.",
                "category": "company",
                "datetime": 1782271678,
                "headline": "LLY Stock Rides Trump Spotlight: President Touts Eli Lilly’s $3.5B Factory As Weight-Loss Pill Plans Go Global"
              },
              {
                "id": 140709046,
                "url": "https://finnhub.io/api/news?id=fd5cfb3ddfda0299e863eb8745d12c548160eb1e1b6546a61f235a8dbdfa3bd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, as an independent director effective June 16, 2026. His background in drug discovery, clinical development, and precision medicine across cardiometabolic, immunology, and neuroscience fields aligns closely with Illumina’s push into clinical genomics and multiomics. We’ll now examine...",
                "category": "company",
                "datetime": 1782263536,
                "headline": "Adding Eli Lilly’s R&D Chief to the Board Might Change The Case For Investing In Illumina (ILMN)"
              },
              {
                "id": 140709047,
                "url": "https://finnhub.io/api/news?id=a7b8c99a209076db590a03c0441ea90e925e9723e258a010a5c916ca47b3bd9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Abbisko Therapeutics Co., Ltd. (\"Abbisko Therapeutics\" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (\"Lilly\"), a leading global pharmaceutical company. Under the agreement, the two companies will collaborate on the discovery and development of innovative medicines across multiple targets, advancing novel drug candidates with global potential.",
                "category": "company",
                "datetime": 1782262800,
                "headline": "Abbisko Therapeutics Deepens R&D Collaboration with Lilly"
              },
              {
                "id": 140709048,
                "url": "https://finnhub.io/api/news?id=1f88ed59d70acc605ac6e731dd1b2d799ae3d0b5c3545ccf0daeba84a1369fee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The rally reflects broader positive sentiment toward Viking’s lead candidate, VK2735, a dual GLP-1/GIP receptor agonist being developed in both injectable and oral forms for obesity.",
                "category": "company",
                "datetime": 1782258375,
                "headline": "VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation"
              },
              {
                "id": 140709049,
                "url": "https://finnhub.io/api/news?id=730aac618736f73923a256a5484b639aae898ab0da37051ef3cd0e3ec992cdba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly's expected global sales of $137 billion in 2032 will be driven by its weight-loss drugs.",
                "category": "company",
                "datetime": 1782254183,
                "headline": "Thinking Thin Pays Off: Lilly To Dominate Pharma World By 2032"
              },
              {
                "id": 140706975,
                "url": "https://finnhub.io/api/news?id=f63b02dc0aac10355a9f7054c155d5f16ba173edcf55f023123366ee989c7462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.",
                "category": "company",
                "datetime": 1782245820,
                "headline": "Biotech's Silent Resurgence (5-Year Base Breakout)"
              },
              {
                "id": 140706976,
                "url": "https://finnhub.io/api/news?id=40cea8fb275d861a3becf0bae0ceea497224f2f0a3b6e14fb3a81a0e9b67bd1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.",
                "category": "company",
                "datetime": 1782244632,
                "headline": "The $50B Plan Merck Stock Was Broadcasting"
              },
              {
                "id": 140706977,
                "url": "https://finnhub.io/api/news?id=de3e22acd75312738f7821622894268295e29fa7913d3c81cfb508d8fc70c4cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is among the Best Pharmaceutical Stocks. On June 5, Eli Lilly and Company (NYSE:LLY) CEO David Ricks said on The Prof G Pod that GLP-1 drugs “will turn out to be a more transformative technology than artificial intelligence.” He called artificial intelligence “overhyped” and GLP-1s “underhyped,” according to the interview. Ricks […]",
                "category": "company",
                "datetime": 1782244530,
                "headline": "Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America"
              },
              {
                "id": 140704246,
                "url": "https://finnhub.io/api/news?id=0ddf0c18192d2151603ab2cb958daf8453e200dd438311e612d17e0b24c01616",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State S",
                "category": "company",
                "datetime": 1782236323,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 140704139,
                "url": "https://finnhub.io/api/news?id=26cea4ee33a30045076867f771332fbb3ac2b8a09e72117289c2351a9f598156",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "BioNeMo Agent Toolkit launches with more than 50 adopters including Anthropic, OpenAI, Eli Lilly",
                "category": "company",
                "datetime": 1782235397,
                "headline": "Nvidia Targets a $300 Billion Pharma Market"
              },
              {
                "id": 140704248,
                "url": "https://finnhub.io/api/news?id=ba7e08bb576f9e5c34db2e69fa2e5375aa8e8d7fbc0179f5d765b4ff4389698b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly's 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company's hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look.",
                "category": "company",
                "datetime": 1782234181,
                "headline": "How Eli Lilly's CEO Plans to Defeat Pharma's Boom-Bust Cycle"
              },
              {
                "id": 140704249,
                "url": "https://finnhub.io/api/news?id=512907bc8c37276cae5e0dc23bdfd9fc6a50b447c2c52783e7f2278cddc41bef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Report says FDA and Lilly allowed one patient to receive experimental obesity treatment retatrutide.",
                "category": "company",
                "datetime": 1782233420,
                "headline": "Lilly Drug Access Draws Attention"
              },
              {
                "id": 140704866,
                "url": "https://finnhub.io/api/news?id=6a016defe1b9dc53f0a16467941078ed767221dc5a1d439272f088d00e57048c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222145/image_2194222145.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "After lagging expectations during recent market volatility, the healthcare sector is showing signs of strength. TD Asset Management's Jacky He explains what's driving the sector’s rebound.",
                "category": "company",
                "datetime": 1782226200,
                "headline": "Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities"
              },
              {
                "id": 140702516,
                "url": "https://finnhub.io/api/news?id=7e0feacb8c9a952fe65a5cbcf1de6f5b54d8be3e3850ecd66ea50821e8814ff8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.",
                "category": "company",
                "datetime": 1782225240,
                "headline": "Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?"
              },
              {
                "id": 140705235,
                "url": "https://finnhub.io/api/news?id=af20db35f183e9402b4374ce80166ceb2856ee7ab28087d5b6a6bebd6f4b664e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/23/Gene-editing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.",
                "category": "company",
                "datetime": 1782222396,
                "headline": "Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle"
              },
              {
                "id": 140701421,
                "url": "https://finnhub.io/api/news?id=4882d0258ab7c60205547e47d470a52e1ce233fe4c4529efaeba914479a20135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms.",
                "category": "company",
                "datetime": 1782219900,
                "headline": "Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors"
              },
              {
                "id": 140702517,
                "url": "https://finnhub.io/api/news?id=4445eeea8d4c68cec7af37eb8b8523ff52deb5adc37c528cc2712f0bfee5a7d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1782219607,
                "headline": "Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock"
              },
              {
                "id": 140701423,
                "url": "https://finnhub.io/api/news?id=408cb6795af87aaea486431bc840b4a96b8798d40e8208ba830ed92439352666",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SAN FRANCISCO & INDIANAPOLIS, June 23, 2026--ŌURA, maker of the world’s most trusted smart ring, Oura Ring, and LillyDirect, Eli Lilly and Company’s digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need, today announced a collaboration enabling savings on the Oura Ring sizing kit. The companies will coordinate to improve access to prescribed treatment and integrated behavioral support tools that complement presc",
                "category": "company",
                "datetime": 1782219600,
                "headline": "ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options"
              },
              {
                "id": 140701321,
                "url": "https://finnhub.io/api/news?id=1ff422fe7dd6e39cb8b9568122968a3d6fd20f54f558a8f79c1dde653957afe5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVIDIA BioNeMo Agent Toolkit NVIDIA BioNeMo Agent Toolkit provides domain-specific tools and skills for the agentic life sciences era. News Summary: Industry and research leaders including Dassault Systèmes, Databricks, Lilly, OpenAI, Schrödinger, Snowflake, the UW Medicine Institute for Protein Design and dozens others are adopting, and Anthropic and OpenAI are integrating, NVIDIA BioNeMo Agent Toolkit to bring agentic life sciences workflows to researchers and scientists.NVIDIA BioNeMo Agent T",
                "category": "company",
                "datetime": 1782219600,
                "headline": "NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery"
              },
              {
                "id": 140701424,
                "url": "https://finnhub.io/api/news?id=acc1bcc176bdb1a262a92f74c4fe7e17920d346a5ee49fa110cc79cbaed6ee33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today a",
                "category": "company",
                "datetime": 1782216300,
                "headline": "Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas"
              },
              {
                "id": 140703322,
                "url": "https://finnhub.io/api/news?id=ba8c611797cf221d9acb047626bd4ce816fc2e992120d4d71cbef4571cf98c87",
                "image": "https://image.cnbcfm.com/api/v1/image/108225866-1763076912827-IMG_9936.jpg?v=1763126426&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "A new regime of trillion-dollar companies is replacing the 'Magnificent Seven.'",
                "category": "company",
                "datetime": 1782215490,
                "headline": "Could there be a $10 trillion company? Tech investing star Laffont thinks so"
              },
              {
                "id": 140703324,
                "url": "https://finnhub.io/api/news?id=9018b5e3e2278ce4a24d62bcac295dc88469fe2a7aeda91dfc362357890233ec",
                "image": "https://image.cnbcfm.com/api/v1/image/108325499-17822283421782228337-46725500055-1080pnbcnews.jpg?v=1782228340&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Jack Hidary, SandboxAQ CEO, joins 'Squawk on the Street' to discuss the company's partnership with Nvidia, any precedents to do this deal and much more.",
                "category": "company",
                "datetime": 1782214403,
                "headline": "SandboxAQ CEO on Nvidia deal: Creates screening tool to help drug developers identify candidates"
              },
              {
                "id": 140706622,
                "url": "https://finnhub.io/api/news?id=70bf83f4ef755c5597c4974f8a472b2cfafe2a24551bd1fabe3d04c7b40814b4",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.ft.com/content/d524396a-4986-46e9-9a93-a982e330d157?syn-25a6b1a6=1",
                "category": "company",
                "datetime": 1782210775,
                "headline": "Reported June 22: 'Eli Lilly deploys weight-loss cash on ‘App Store’ for scientists' - Financial Times"
              },
              {
                "id": 140700213,
                "url": "https://finnhub.io/api/news?id=45dfd7f478ecb84afc48a229817ec8284c31fb9957063609ac21eb68dc719aed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CAMBRIDGE, England, June 23, 2026--TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million). The financing was led by Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.",
                "category": "company",
                "datetime": 1782207420,
                "headline": "TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio"
              },
              {
                "id": 140700214,
                "url": "https://finnhub.io/api/news?id=28f3c648dd75c993cd76e605be26b35048116a5ef73200bb11af0582f72ce72e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "BioArctic will create a new drug candidate using its BrainTransporter platform and Lilly’s molecule.",
                "category": "company",
                "datetime": 1782207125,
                "headline": "Lilly and BioArctic sign deal to develop neurodegenerative therapy"
              },
              {
                "id": 140705236,
                "url": "https://finnhub.io/api/news?id=63bfc8de3f2b00432a762febbb5cb65943ced6851a6351c3ec0459fdd9ecb879",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.sec.gov/ix?doc=/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm",
                "category": "company",
                "datetime": 1782204943,
                "headline": "Sangamo Therapeutics Files For Chapter 11 Bankruptcy, Secures Up To $30M In Debtor-In-Possession Financing; Launches Court-Supervised Asset Sale Process With Eli Lilly And Astellas As Stalking Horse Bidders For Key Gene Therapy, Genome Editing, And Fabry Disease Assets; Expects Restructuring To Result In Elimination Of About 51 Roles In U.S., Or About 40% Of Company's Workforce"
              },
              {
                "id": 140703399,
                "url": "https://finnhub.io/api/news?id=26fb003afbd9a170e9afccc8bbb86fe331d555eb1011a55434149e849f1db780",
                "image": "https://image.cnbcfm.com/api/v1/image/108325354-17822155451782215541-46722430255-1080pnbcnews.jpg?v=1782215544&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Philippe Laffont, Coatue Management founder and portfolio manager, joins 'Squawk Box' to discuss the state of the AI boom, AI power demand, SpaceX IPO, latest market trends, his thoughts on chip stocks, bitcoin, agentic AI, and more.",
                "category": "company",
                "datetime": 1782201701,
                "headline": "Billionaire investor Philippe Laffont: There will be a $10 trillion company in the future"
              },
              {
                "id": 140699696,
                "url": "https://finnhub.io/api/news?id=2623aa764b291fd09bf1954e0d855be9af6d642f29b77d25e734414f80f73bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "They look well-positioned to grab a slice of the fast-growing anti-obesity market.",
                "category": "company",
                "datetime": 1782198300,
                "headline": "2 Underrated Weight Loss Stocks to Buy and Hold"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 247,
            "discarded_article_count": 219
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 3362660,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 3549610,
              "avg_vol_20": 3406715,
              "avg_vol_30": 3362660,
              "range_pct_10": 0.12850854858484168,
              "range_pct_20": 0.12850854858484168,
              "range_pct_30": 0.17481950654830974,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0555958675572314,
              "dist_to_20d_high": 0.001970872374798044,
              "down_shrink_days": 2,
              "breakout_level_20d": 1238,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.735092731481481
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.5,
            "details": {
              "atrPct": 3.209475709339455,
              "turnoverUsdM": 3582.5323407312603,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.LLY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 1156.2501,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.5,
            "stop_loss_percent": 6.4,
            "take_profit_price": 1351.8814,
            "target_multiplier": 2.2,
            "technical_strength": 2,
            "take_profit_percent": 9.4
          },
          "positionPoints": 1.5,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.4644136381288617,
          "stopLossPercent": 6.41895141867891,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 39.655,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.21
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 147.76
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0663
    },
    "kdj": {
      "d": 73.72,
      "j": 95.22,
      "k": 80.88,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 60.56
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 8581821,
      "recentSlope": 1447872.1,
      "previousSlope": -1214650
    },
    "rsi": 69.53,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 1127.6568,
      "position": "SAR喺價下",
      "distancePct": 8.73,
      "previousTrend": "上升"
    },
    "ma50": 1066.8518,
    "macd": {
      "macd": 40.5934702569848,
      "trend": "強烈看漲",
      "signal": 36.240556609458324,
      "histogram": 4.352913647526478
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 1158.7684,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 8
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.87,
      "score": 4,
      "avgVolume": 3345381,
      "currentVolume": 2899521
    },
    "derived": {
      "ma20": 1155.9715,
      "ma50": 1066.8518,
      "prevClose": 1200.0601,
      "avgVolume10": 3538062,
      "avgVolume20": 3345381,
      "changePercent": 2.96,
      "avgVolumeForScore": 3345381
    },
    "ma_cross": {
      "ma20": 1155.9715,
      "ma50": 1066.8518,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 1150.7645,
      "prevMa50": 1060.4936,
      "spreadPct": 8.35,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 1067.9332,
      "upper": 1244.0098,
      "position": "上半部"
    },
    "rsi_short": 60.43,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.87
    }
  }
}

{
  "close": 1235.56,
  "volume": 2899521,
  "changePercent": 2.96
}